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Abstract 
The high-grade serous carcinoma (HGSOC) is the most common ovarian cancer 
type that, due to late diagnosis, has the highest mortality rate of all gynecological 
cancers. One third of the patients develop a fluid in the peritoneal cavity called 
ascites. The ascites contains tumor and immune cells as well as soluble 
immunomodulatory factors such as cytokines. 
NK cells - as a crucial part of the innate immune system - play a major role in 
tumor immune surveillance. Their effector function is tightly regulated by the 
balance between activating and inhibitory receptor signaling. However, NK cell 
function of many tumor patients is restricted and the overall results of NK cell-
based immunotherapy are unsatisfying. This is often due to tumor-associated 
immune escape mechanisms. 
One of the best characterized activating receptors of NK cells is NKG2D, which 
recognizes malignant cells and mediates tumor cell lysis. However, in various 
tumor entities, the NKG2D/NKG2D-Ligand (NKG2D-L) signaling axis is defective. 
Shedding of NKG2D-Ls from the surface of tumor cells to a soluble form is one 
such evasion strategy. The interference mechanisms of the ligands include (1) 
the downregulation of NKG2D and (2) passive blocking of NKG2D. Subsequently, 
this leads to dysfunctional NK cells and facilitated tumor growth. However, in 
mice, (3) they can also inhibit the NKG2D/NKG2D-L macrophage – NK cell 
crosstalk and thereby support NK cell-mediated tumor cell lysis. The relevance 
of this mechanism in humans is elusive. 
In ovarian cancer ascites, soluble NKG2D-Ls are enriched and negatively 
correlate with the survival of the patients. Surprisingly, the expression of NKG2D 
on NK cells and T cells is not reduced. In this thesis, I could show that human 
macrophages did not express NKG2D excluding a direct interaction of NKG2D-Ls 
with macrophages. However, NKG2D-Ls were detectable on the surface of 
macrophages, but the killing of macrophages by NK cells was not NKG2D-
dependent. This indicates that, in ovarian cancer, soluble NKG2D-Ls do not 
influence the NKG2D signaling through the mechanisms described so far in other 
models. Instead, I provided evidence that soluble NKG2D-Ls have an additional 
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function – namely the induction of NKG2D signaling and target gene expression 
upon engagement. 
Furthermore, not much is known about the phenotype and differentiation of 
healthy NK cells to tumor-associated NK cells (TANKs) and in particular about 
signaling pathways that are involved. In this thesis, I showed that patient-derived 
NK cells depicted a mixed tumor-associated phenotype, in which NK cells 
displayed a strong downregulation of most of the activating receptors and an 
upregulation of the inhibitory receptors PD-1 and TIM-3, indicating a state of 
exhaustion. These NK cells showed impaired NK cell effector functions, which 
could be restored upon cytokine activation and blockage of the TGFβ signaling 
pathway. Moreover, TANKs showed a dysregulation of the natural killer cell-
mediated cytotoxicity and the Hippo pathways. I established that proteins 
suppressed by the Hippo pathway, such as YAP1 and TEAD4, were exclusively 
expressed in TANKs, while they were absent in healthy donor NK cells. However, 
if healthy donor NK cells were stimulated with TGFβ, IL-2 and via CD16 
crosslinking, expression of TEAD4 was induced. TEAD4-expressing NK cells 
showed a TEAD4-dependent upregulation of TIM-3. Finally, I provided first 
evidence that TEAD4-expressing NK cells could acquire a regulatory function, in 
which they were able to suppress T cell proliferation. 
These findings shed more light on the role of NK cells in the tumor 
microenvironment (TME) of ovarian cancer patients. Based on that, further 
research will increase our knowledge of NK cell tumor surveillance, paving the 
way for strategies boosting anti-tumor NK cell functions.  
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Zusammenfassung 
Das seröse Ovarialkarzinom (HGSOC) ist die häufigste Art von Eierstockkrebs, 
der aufgrund einer späten Diagnose die höchste Mortalitätsrate von allen 
gynäkologischen Krebserkrankungen aufweist. Ein Drittel der Patientinnen 
entwickeln eine Flüssigkeit im Peritonealraum, die Aszites genannt wird. Dieser 
Aszites enthält Tumor- und Immunzellen so wie lösliche, immunmodulierende 
Faktoren wie etwa Zytokine.  
NK-Zellen – als wichtiger Teil des angeborenen Immunsystems – spielen eine 
wesentliche Rolle in der tumor immune surveillance. Ihre Effektorfunktion ist 
durch das Gleichgewicht zwischen aktivierenden und inhibierenden 
Rezeptorsignalen streng reguliert. Die NK-Zellfunktion von vielen 
Tumorpatientinnen ist eingeschränkt und die Ergebnisse von NK-Zell-basierten 
Immuntherapien sind bislang unbefriedigend. Dies liegt oftmals an Tumor-
assoziierten Immunevasions-Mechanismen.  
Einer der am besten charakterisierten aktivierenden Rezeptoren von NK-Zellen 
ist NKG2D, welcher maligne Zellen erkennt und die Tumorzell-Lyse vermittelt. 
Jedoch ist die NKG2D/NKG2D-Ligand (NKG2D-L)-Signalachse in vielen 
Tumorentitäten gestört. Das Abspalten („shedding“) von NKG2D-L von der 
Oberfläche der Tumorzellen zu einer löslichen Form ist eine solche 
Evasionsstrategie. Die Störungsmechanismen der Liganden beinhalten (1) die 
Runterregulation von NKG2D und (2) das passive Blockieren von NKG2D. In der 
Folge führt dies zu dysfunktionalen NK-Zellen und einem begünstigten 
Tumorwachstum. Allerdings können sie (3) in der Maus auch den 
NKG2D/NKG2D-L Makrophagen – NK-Zell Crosstalks inhibieren und dadurch die 
NK-Zell-vermittelte Tumorzell-Lyse fördern. Die Relevanz dieses Mechanismus 
im Menschen ist bisher unerforscht. 
Im Ovarialkarzinom-Aszites sind lösliche NKG2D-L angereichert und korrelieren 
negativ mit dem Überleben der Patientinnen. Erstaunlicherweise ist die 
Expression von NKG2D auf NK-Zellen und T-Zellen nicht reduziert. In dieser 
Dissertation konnte ich zeigen, dass Makrophagen kein NKG2D exprimieren und 
somit nicht direkt mit löslichen NKG2D-L interagieren. Des Weiteren war die Lyse 
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von Makrophagen durch NK-Zellen nicht NKG2D-abhängig. Dies weist darauf 
hin, dass im Ovarialkarzinom die löslichen NKG2D-L die NKG2D-
Signalvermittlung nicht durch Mechanismen beeinflussen, die bereits in anderen 
Modellen beschrieben wurden. Stattdessen konnte ich eine weitere, neue 
Funktion von löslichen NKG2D-L beschreiben, nämlich die Induktion der NKG2D-
Signalvermittlung und damit die Expression von Zielgenen nach ihrer Bindung.  
Des Weiteren ist der Phänotyp und die Differenzierung zu Tumor-assoziierten 
NK-Zellen (TANKs) und insbesondere die involvierten Signalwege noch 
unvollständig untersucht. In dieser Dissertation konnte ich zeigen, dass NK-
Zellen von Patientinnen einen gemischten, Tumor-assoziierten Phänotyp 
aufwiesen. Bei diesem zeigten die NK-Zellen eine starke Runterregulation der 
meisten aktivierenden Rezeptoren, sowie eine Hochregulation von PD-1 und 
TIM-3, was auf einen anergen Status der NK-Zellen hinweist. Diese NK-Zellen 
zeigten gestörte NK-Zell-Effektorfunktionen, die durch eine Zytokinaktivierung 
und die Blockierung der TGFβ-Signalvermittlung wiederhergestellt werden 
konnten. Darüber hinaus zeigten TANKs eine Dysregulation des kegg pathways 
natural killer cell-mediated cytotoxicity und des Hippo pathways. Proteine, die 
durch den Hippo pathway reprimiert werden, wie beispielsweise YAP1 und 
TEAD4, waren ausschließlich in TANKs exprimiert, während sie in gesunden NK-
Zellen nicht nachweisbar waren. Wurden jedoch gesunde NK-Zellen mit TGFβ, 
IL-2 und durch CD16-crosslinking stimuliert, so wurde die TEAD4-Expression 
induziert. TEAD4-exprimierende NK-Zellen zeigten eine TEAD4-abhängige 
Hochregulation von TIM-3. Schließlich konnte ich erste Hinweise erbringen, dass 
TEAD4-exprimierende NK-Zellen eine regulatorische Funktion erlangen können, 
durch welche sie in der Lage sind, die Proliferation von T-Zellen zu unterdrücken. 
Diese Erkenntnisse werfen mehr Licht auf die Rolle von NK-Zellen in der Tumor-
Mikroumgebung (tumor microenvironment, TME) von Ovarialkarzinom-
Patientinnen. Darauf basierend wird weitere Forschung unser Wissen über NK-
Zell tumor surveillance vergrößern, was den Weg für Strategien, die anti-
tumoröse NK-Zell-Funktionen zu verstärken, ebnet.   
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1 Introduction 
The immune system is a powerful tool to control and eliminate tumors. However, 
in many cancers, the immune system is affected in multiple ways leading to 
impaired immune surveillance [71]. One of those cancers is ovarian cancer [232]. 
Therefore, it is essential to understand the molecular and phenotypical changes 
of the tumor microenvironment in ovarian cancer to improve immunotherapy 
options and the outcome of the patients.  
1.1 Natural Killer cells recognize and eliminate malignant cells 
Natural Killer (NK) cells are lymphocytes belonging to the innate immune system. 
They are classically identified by the expression of the surface markers CD56 
and the lack of CD3 expression. They can further be classified into two subsets: 
CD56bright and CD56dim NK cells. While the CD56dim NK cells express high levels 
of CD16 and moderate levels of CD56, CD56bright NK cells express low amounts 
of CD16 and high amounts of CD56. In the peripheral blood of healthy individuals, 
90 % of the NK cells are CD56dim NK cells and the remaining 10 % are CD56bright 
NK cells [51]. CD56bright NK cells are predominantly found within the lymph nodes, 
produce higher amounts of cytokines, such as interferon gamma (IFNγ) and 
tumor necrosis factor alpha (TNFα), and represent a more immature status of the 
NK cells. Conversely, CD56dim NK cells produce low amounts of cytokines but 
exhibit a higher cytotoxic potential [51] [219].  
As part of the innate immune system, NK cells are able to recognize and kill virus-
infected or malignant cells. Upon activation, NK cells release cytotoxic granules 
filled with perforin and granzyme. Perforin integrates into the membrane of the 
target cells where it forms pores, through which granzymes, belonging to the 
serine proteases, can enter. Here, granzymes induce the apoptosis of the cell by 
activation of caspases and the pro-apoptotic BH3-interacting domain death 
agonist (BID) [3] [193]. 
Embedded in the membrane of the cytotoxic granules is the lysosomal-
associated membrane protein-1 (LAMP-1 or CD107a). CD107a can be detected 
on the surface of NK cells upon fusion of the cytotoxic granules with the plasma 
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membrane. A higher expression of CD107a on the surface of NK cells positively 
correlates with the release of cytokines and the lysis of the target cell. Therefore, 
CD107a expression can be used as a marker for the cytotoxic activity of NK cells 
[2] [4].  
Moreover, NK cells also kill target cells through the initiation of the extrinsic 
apoptosis pathway induced by the death ligands TNF-related apoptosis-inducing 
ligand (TRAIL), CD95L (Fas ligand) or TNFα [104] [130] [152] [243]. 
1.1.1 Activating and inhibitory receptors of NK cells regulate NK cell 
function 
As NK cells possess a high cytotoxic potential, their regulation needs to be tightly 
controlled. Therefore, they express a variety of receptors, so-called activating 
receptors and inhibitory receptors (Introductory Fig. 1). The balance between 
those receptors is crucial for the activation of the cell and is necessary to 
distinguish between healthy cells (“self”), virus-infected cells (“missing self”) or 
malignant cells (“induced-self”).  
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Introductory Fig. 1 (modified from Leung, 2014 [122]): NK cell receptors and their ligands.  
Shown are numerous activating (depicted in green) and inhibitory receptors (illustrated in red) 
expressed on NK cells, as well as cytokine receptors (displayed on the top). Co-receptors are 
marked with stripes. Ligands of the receptors are shown in brackets. 
If the NK cell encounters a healthy cell, the inhibitory receptors will recognize the 
major histocompatibility complex (MHC) class I molecules expressed on the 
surface of the healthy cell and an inhibitory signal will be sent to the NK cell, 
protecting the healthy cell from NK cell-mediated lysis [155] [241].  
If the cell is transformed or infected by a virus, MHC class I molecules are 
downregulated to escape recognition by cytotoxic T cells (CTLs) [31] [170]. 
However, now NK cells are no longer inhibited by the inhibitory signal of their 
receptors and solely the activating receptor signal is transmitted. Hence, the NK 
cell is activated, leading to the lysis of the malignant cell [103]. This phenomenon 
is called the “missing-self” hypothesis [134]. 
In addition, if a cell is stressed, activating ligands are upregulated. Hence, the 
signal of the activating receptor outweighs the inhibitory receptor signal, the NK 
cell is activated and the target cell is killed – known as the “stress-induced self” 
hypothesis [39] [220].  
Summing up, the NK cell effector function is tightly controlled by the balance 
between activating and inhibitory receptor signaling.  
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1.1.1.1 The CD94/NKG2 family modulates NK cell functions  
The NK group 2 member (NKG2) family mainly consists of activating receptors 
but also contains inhibitory receptors. They belong to the C-type lectin-like 
receptor superfamily and most of the family members (NKG2-A, -B, -C, -E and -H) 
build disulfide-linked heterodimers with CD94 [16] [22] [116]. They bind the non-
classical MHC class I molecule human leukocyte antigen (HLA)-E in humans 
[20] [25]. 
NKG2A and NKG2B are inhibitory receptors that are transcribed by the same 
gene but are alternatively spliced. Furthermore, they contain two immunoreceptor 
tyrosine-based inhibitory motifs (ITIM) in their cytoplasmic domains [26] [37]. It 
has been revealed that NKG2A is upregulated on the plasma-membrane of 
breast cancer patient-derived NK cells, which correlated with a reduced NK cell 
cytotoxicity [139].  
NKG2C, NKG2E, and NKG2H lack the ITIM, but instead have a positively 
charged residue in their transmembrane domain, which can bind to the 
immunoreceptor tyrosine-based activating motif (ITAM) of the adaptor protein 
DNAX-activation protein (DAP) 12. NKG2E and NKG2H are alternatively spliced 
variants of the same gene. NKG2C, NKG2E, and NKG2H are all described to be 
activating receptors [16] [114] [215].  
One of the most studied activating receptors recognizing malignant cells is 
NKG2D [10]. NKG2D is expressed on NK cells, all CD8+ T cells and some γδ T 
cells, NKT cells and CD4+ T cells [179]. Moreover, it does not associate with 
CD94 [233].  
NKG2D forms a homodimer and associates with the adaptor molecule DAP10 in 
humans and DAP10 and DAP12 in mice [77] [233]. Upon engagement with its 
ligands, NKG2D recruits DAP10, which contains an Src Homology 2 (SH2) 
domain-binding site. This then leads to an activation of the phosphatidylinositol-
4,5-bisphosphate 3-kinase (PI3K)/Akt signaling cascade triggering cytokine 
release and killing of the target cell [179] [233].  
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In humans, eight NKG2D ligands (NKG2D-Ls) exist, which belong to the major 
histocompatibility complex class I-related chain (MIC) A/B [10] or to the UL16 
binding protein (ULBP1-6) family [40] [52] [61] [62]. Those families are MHC class 
I related glycoproteins. The NKG2D-Ls bind with different avidities to the receptor, 
but nothing is known about the distinct role of each ligand so far [150] [179]. In 
mice, NKG2D binds to retinoic acid early inducible gene 1 (Rae-1) proteins 
(Rae1α, β, γ, δ, ε) [38], members of the histocompatibility 60 (H60) protein family 
(H60a, b, c) [59] and murine UL16 binding protein-like transcript (MULT-1) 
[35] [41].  
In order to escape immune recognition, malignant cells are able to shed their 
NKG2D-Ls from the surface via metalloproteases [46] [187] [222] or release them 
via exosomes [7] [46] [68]. These soluble ligands can bind to NKG2D, induce the 
internalization of NKG2D and hence impair NK cell function [80] [202]. Elevated 
levels of soluble NKG2D-Ls are detectable in various tumor entities, resulting in 
diminished cytotoxicity of NK cells [100] [141] [188]. High levels of soluble 
NKG2D-Ls were also measured in the ascites of ovarian cancer patients, but the 
expression of NKG2D was not diminished on patient-derived NK cells [221]. 
Moreover, the function of NKG2D-Ls on exosomes is still controversially 
discussed. It is hypothesized that their function rather depends on the type of 
exosome-releasing cell. While tumor cell-derived exosomes can inhibit the NK 
cell function, exosomes released by dendritic cells (DCs) can activate NK cells 
[50] [136] [217].  
Finally, to escape immune surveillance, tumor cells can remodel the tumor 
microenvironment (TME) via the NKG2D/NKG2D-L axis. In mice, Qian et al. 
showed that RAE1ε-expressing tumor cells induce the generation of myeloid-
derived suppressor cells (MDSCs) via NKG2D. Those MDSCs secrete IL-10, 
suppress CD8+ T cell proliferation and thereby promote tumor growth [177].  
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1.1.1.2 Natural cytotoxicity receptors (NCRs) – an important family for 
tumor immune surveillance 
Another prominent family of NK cell receptors are the NCRs, which are mainly 
activating receptors and comprises three family members – natural killer cell 
protein 30 (NKp30), NKp44 and NKp46 [166] [199] [218]. In acute myeloid 
leukemia (AML) it was shown that NCRs are downregulated resulting in a weak 
cytotoxic activity of NK cells [53]. 
NKp30 binds to several ligands, one of them is B7-H6, which is the only known 
transmembrane protein among them [24]. An intracellular ligand is BCL2-
associated athanogene 6 (BAG6) [173], which can be secreted in a soluble form 
or associated with extracellular vesicles (EVs). When BAG6 is secreted in a 
soluble form, it exhibits an inhibitory function, while it has an activating function 
when BAG6 is EV-associated [184] [197]. Another soluble ligand for NKp30, 
which inhibits NK cell function, is Galectin-3 [226]. Furthermore, NKp30 has three 
splice variants – NKp30a, b, and c. NKp30a and b are immunostimulatory 
isoforms, while NKp30c displays an immunosuppressive isoform [57].  
NKp44 binds to the activating ligand NKp44L, an isoform of mixed lineage 
leukemia 5 (MLL5) protein, expressed on the surface of transformed cells [11], 
and to the inhibitory ligand proliferating cell nuclear antigen (PCNA) [186].  
Moreover, NKp46 binds to vimentin, expressed on the surface of mycobacterium 
tuberculosis-infected human monocytes or activated CD4+ T cells [47] [75]. 
NKp46 is selectively expressed on NK cells, making it a good marker for NK cells 
[72] [168].  
Finally, all NCRs bind to heparan sulfate on malignant cells [89].  
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1.1.1.3 The killer cell immunoglobulin-like receptor (KIR) family has diverse 
functions in NK cell regulation 
KIRs are transmembrane glycoproteins, which are expressed by NK cells and a 
subset of T cells. The KIR family consists of 14 highly polymorphic genes and the 
receptors can transmit either activating or inhibitory signals. Activating KIRs have 
a short cytoplasmic domain, which associates with DAP12 to transfer an 
activating signal. Conversely, all inhibitory KIRs have a long cytoplasmic domain, 
which contains an ITIM needed to transmit the inhibitory signal. Examples of 
activating receptors are KIR2DL4 (CD158d), KIR2DS1 (CD158h) and KIR2DS2 
(CD158j), and inhibitory receptors are KIR2DL1 (CD158a), KIR2DL2 (CD158b1), 
KIR2DL3 (CD158b2) and KIR3DL1 (CD158e1). The ligands of KIRs are MHC 
class I molecules (Table 1) [34] [74]. However, the avidity of inhibitory KIRs is 
higher than the avidity of activating KIRs [34] [206]. 
Table 1: KIRs and their ligands. 
KIRs HLA ligands Signaling 
KIR2DL1 HLA-C2 Inhibitory 
KIR2DL2 HLA-C1 Inhibitory 
KIR2DL3 HLA-C1 Inhibitory 
KIR2DL4 HLA-G Activating 
KIR2DS1 HLA-C2 Activating 
KIR2DS2 HLA-C1 Activating 
KIR3DL1 HLA-Bw4 Inhibitory 
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1.1.1.4 Other receptors involved in modulating NK cell activity 
One of the most important activating receptors on NK cells is CD16, the low 
affinity Fc receptor FcγRIII, which is responsible for the antibody-dependent cell-
mediated cytotoxicity (ADCC) response of NK cells. Here, the Fc part of the 
immunoglobulin G (IgG) binds to CD16 triggering the cytotoxic response of NK 
cells [227]. It was shown that CD16 is strongly downregulated on NK cells of 
ovarian cancer patients, thus preventing a strong NK cell-mediated anti-tumor 
response [221].  
DNAX Accessory Molecule-1 (DNAM-1; also called CD226) is an activating 
receptor of human NK cells, belonging to the Ig superfamily [115]. It is also 
expressed by a subset of B cells, monocytes, T cells and platelets [195]. DNAM-1 
binds to polio virus receptor (PVR) (also called CD155) and nectin-2 (also known 
as CD112). Upon engagement of DNAM-1 with its ligands, NK cells are activated, 
leading to the killing of the target cell and a release of cytokines such as IFNγ 
[23] [209]. PVR and nectin-2 are frequently overexpressed on tumor cells, such 
as lung adenocarcinoma [157], colorectal carcinoma [143], pancreatic cancer 
[161] or melanoma [18] and correlate with tumor progression and a poor 
prognosis [18] [157] [162]. However, in AML, PVR and nectin-2 are 
downregulated in order to escape recognition by NK cells showing that the tumor-
associated NK cells (TANKs) are shaped by the TME [105]. Moreover, it was 
observed that DNAM-1 is downregulated on patient-derived NK cells in ovarian 
cancer [36], myeloma [63] and breast cancer [139]. 
T cell immunoglobulin and ITIM domain (TIGIT), an immunosuppressive receptor, 
is expressed by T cells, T regulatory cells (Tregs) and NK cells and just like 
DNAM-1 it binds to PVR and nectin-2. Engagement of PVR on DCs with TIGIT-
expressing T cells leads to a release of interleukin 10 (IL-10) and a decreased 
secretion of proinflammatory cytokines. Furthermore, the ITIM of TIGIT is 
important for the inhibition of NK cell-mediated cytotoxicity [131] [204] [242]. 
Besides the inhibition of T cells by DC-released IL-10, TIGIT can also directly 
inhibit the T cell’s function via cell-intrinsic signaling [102]. TIGIT binds PVR with 
much higher affinity than DNAM-1 and thus outcompetes DNAM-1 [5]. Moreover, 
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TIGIT can directly interact with DNAM-1 in cis and prohibits the homodimerization 
of DNAM-1 and its function [101]. TIGIT is upregulated on tumor patient-derived 
T cells and NK cells, leading to an exhaustion of the cells and tumor progression. 
Blockage of TIGIT seems to be a promising therapeutic option to restore the 
cytotoxic function of the immune cells [44] [247].  
2B4 was initially described as an activating receptor of NK cells in human and 
mice, but it is also expressed on a subset of CD8+ T cells, γδ T cells, monocytes, 
basophils and eosinophils [162]. 2B4 is activated by the engagement with CD48, 
which is broadly expressed on hematopoietic cells [27]. In IL-2-activated NK cells, 
it can signal on its own, but it can also support the signaling of other activating 
receptors, such as the NKp46, NKG2D and DNAM-1, as a co-stimulatory receptor 
[30] [49] [200]. However, it was also described, that 2B4 can act as a negative 
regulator of murine NK cells, through binding of non–major histocompatibility 
complexes [118]. 
Taken together, NK cells express a variety of activating and inhibitory receptors 
and their signaling is altered in different tumor entities. In order to escape immune 
recognition, tumor cells shed activating ligands form their surface. Moreover, 
activating receptors on tumor-associated NK cells are downregulated, while 
inhibitory receptors are upregulated.  
1.1.2 The exhaustion phenotype of NK cells 
Exhaustion is a state of immune cells, in which their effector function is dampened 
and inhibitory receptors are expressed. This leads to a diminished recognition of 
virus-infected and malignant cells [230]. In NK cells, activating receptors, such as 
NKG2D, DNAM-1, CD16 and the NCRs are downregulated and inhibitory 
receptors, such as programmed death receptor 1 (PD-1), NKG2A and T 
cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) are 
upregulated [13] [17] [19].  
Expression of PD-1 is associated with low cytokine production, diminished 
degranulation and reduced proliferation in response to cytokines [13] [167]. 
Blockage of PD-1 enhances NK cell effector function [17].  
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As a sign of exhaustion, NKG2A expression was increased on NK cells from 
hepatocellular carcinoma patients and was associated with a poor prognosis 
[208]. 
Moreover, TIM-3 was expressed on NK cells of lung adenocarcinoma patients 
leading to a poor prognosis of the patients and a blockage of TIM-3 could 
increase NK cell functions [235].  
Summing up, PD-1 and TIM-3 expression on NK cells mark a state of exhaustion, 
in which the NK cell effector function is impaired and patients displaying 
exhausted NK cells have a poor prognosis.  
1.2 Characteristics of ovarian cancer: Incidence, genetic 
landscape and treatment 
Ovarian cancer has the highest mortality rate of all gynecological cancers 
worldwide [98] [121]. Every seventh reported cancer case in women is epithelial 
ovarian cancer (EOC) with a 5-year survival rate of 46 % due to the late diagnosis. 
Since the course of EOC is mainly asymptomatic, it is diagnosed at an advanced 
stage in 75 % of the cases [124]. The median age of patients at the diagnosis is 
63 years [97]. 
Depending on their histology, EOC can be subdivided into high-grade serous 
ovarian cancer (HGSOC), endometrioid ovarian cancer, clear-cell ovarian 
cancer, low-grade serous ovarian cancer and mucinous ovarian cancer [78].  
HGSOC is the most common type of EOC (75 % of the cases) and over 90 % of 
the patients have a gain-of-function mutation in TP53. Furthermore, 15-20 % of 
the HGSOC patients have a germline mutation of BRCA1 or BRCA2. HGSOC is 
further characterized by chromosomal instability, e.g. insertion and deletion 
mutations. Homologous recombination is defective in half of the cases [15] [124].  
The first-line treatment of HGSOC is the removal of the tumor by primary 
debulking surgery, followed by platinum-based chemotherapy [169]. However, 
over time the tumor cells eventually develop a resistance against platinum leading 
to a relapse in most of the patients. Loss of function of the tumor suppressor 
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genes RB1, NF1, RAD51B, and PTEN play a role during the acquisition of 
chemoresistance, and CCNE1 amplification contributes to primary resistance and 
refractory disease progression [165]. Furthermore, homologous recombination is 
also responsible for platinum-sensitivity in HGSOC [124]. In the SOLO1 trial, 
patients receiving olaparib, a poly (ADP-ribose) polymerase inhibitor, had a 70 % 
lower risk of disease progression or death in comparison to the placebo group. 
Here, patients carrying a BRCA mutation with platinum-sensitive, advanced 
HGSOC were included in the study [154]. Therefore, in 2018, olaparib was 
approved by the US Food and Drug Administration (FDA) for the maintenance 
treatment of patients carrying the BRCA mutations [124]. Conversely, if the cells 
are resistant to platinum, patients are treated with cytotoxic drugs like 
gemcitabine, paclitaxel, topotecan or PEGylated lyposomal doxorubicin, but the 
response rate is low (10-30 %) [140]. Therefore, more trials are run to develop 
new drugs that overcome resistance. In a phase 3 trial (AURELIA) it was reported 
that chemotherapy in combination with bevacizumab (an angiogenesis inhibitor, 
targeting vascular endothelial growth factor (VEGF)) treatment could increase the 
progression-free survival of the patients [176].  
1.2.1 Ascites of ovarian cancer patients have a unique tumor 
microenvironment 
EOC is characterized by rapid growth, spreading into the intraperitoneal site and 
by an accumulation of an effusion, called ascites, in the peritoneal cavity. The 
ascites creates a unique tumor-supportive microenvironment, which consists of 
soluble and cellular components [107] [174] [232] (Introductory Fig. 2). 
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Introductory Fig. 2 (modified from Kipps et al., 2013 [108]): Composition of ovarian cancer 
ascites. 
The ascites is a malignant fluid in the peritoneal cavity of ovarian cancer patients. It consists of 
soluble factors, such as cytokines and chemokines, and of different cell types, such as tumor 
cells, stroma cells, and immune cells.  
1.2.1.1 Soluble factors in the tumor microenvironment of ovarian cancer 
Soluble factors in ascites are cytokines, chemokines, metabolites, proteins, and 
exosomes [107].  
Significantly elevated levels of the pro-tumorigenic cytokines and chemokines 
IL-6, IL‐8, IL‐10, macrophage inflammatory protein 1 beta (MIP‐1β), C-X-C motif 
chemokine ligand 10 (CXCL10), CC-chemokine ligand 2 (CCL2), and VEGF were 
found, while the pro-inflammatory cytokines IL‐2, IL‐5, IL‐7, and IL‐17 were 
reduced [107]. IL-6 and IL-10 levels have been reported to correlate with a poor 
prognosis [112] [180]. Furthermore, VEGF expression correlates with a poor 
prognosis due to increased metastasis [189] [244]. In addition, VEGF promotes 
the accumulation of ascites [32]. Moreover, high levels of the immune-
suppressive cytokine transforming growth factor beta 1 (TGFβ1) are associated 
with reduced relapse-free survival (RFS) [181]. TGFβ induces the expression of 
VEGF in tumor-associated NK cells and thereby remodels the TME [28]. 
Regarding metabolites, changes in the levels of fatty acids, cholesterol, 
ceramide, glycerol‐3‐phosphate, glucose, and glucose‐3‐phosphate were found. 
For example, 2‐hydroxyisovalerate was reduced, while glucose‐1‐phosphate was 
increased [107]. Furthermore, levels of lysophosphatidic acid (LPA) are elevated 
and correlate with short RFS [182]. 
In proteomic studies, Finkernagel et al. identified 779 proteins in the ascites, 
which clustered into groups associated with metastasis and a short RFS (e.g. 
HSPA1A, BCAM, and DKK1), or with immune regulation and a favorable RFS 
(e.g. the protein kinase LCK). Interestingly, most of the proteins that strongly 
associated with the clinical outcome of the patients are components of EVs [70]. 
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EVs are small particles, which consist of nucleic acids, proteins, and lipids. 
Exosomes are a special form of EVs, which are released by the fusion of 
multivesicular bodies with the plasma membrane. EVs can transmit miRNAs, 
which can influence the outcome of the patients [174]. Au Yeung et al. showed 
that EV-associated miR-21 transmits chemoresistance to ovarian cancer cells. 
Here, cancer-associated adipocytes and fibroblasts release miR-21 containing 
EVs which are taken up by ovarian cancer cells, in which miR-21 binds to 
apoptotic peptidase activating factor 1 (APAF1) and thereby suppresses 
apoptosis [8]. Moreover, miR-506 is associated with a good prognosis, while 
miR-433 mediates paclitaxel resistance [228] [238].  
1.2.1.2 Cellular components of the ovarian cancer microenvironment  
Ascites contains tumor cells and heterogeneous stromal cells. The stromal cells 
consist of endothelial or mesothelial cells, fibroblasts, adipocytes, bone marrow‐
derived stem cells, adipose tissue‐derived stromal cells, and immune cells [107]. 
Tumor cells are either present as single cells or as multicellular aggregates, 
known as spheroids. It is proposed, that tumor spheroids are less susceptible to 
chemotherapy in comparison to single cells [196].  
The TME contains various types of immune cells, including effector cells like 
CD4+ and CD8+ T cells, and NK cells. However, the effector cells are inhibited by 
tumor cells, but also by immune-suppressive Tregs, MDSCs, immature DCs and 
tumor-associated macrophages (TAMs) by secretion of immune-suppressive 
chemokines and cytokines [232]. The presence of high numbers of CD3+ 
intratumoral T cells correlates with an improved clinical outcome of the patients 
[246], while high numbers of Tregs are associated with reduced survival [54]. 
Furthermore, a high CD8+/ forkhead box P3 (FoxP3)+ ratio was associated with 
an enhanced disease-specific survival [119].  
Taken together, the composition of the TME plays a critical role in tumor 
progression and is crucial for the prognosis of the patients. Therefore, it is 
important to investigate the function of immune cells in the TME. 
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1.2.2 Therapeutic potential of NK cells in HGSOC 
It was observed, that high numbers of NK cells in ascites of HGSOC lead to 
increased overall survival [90]. However, NK cells from HGSOC patients are 
dysfunctional. They show a reduced proliferation potential, diminished cytotoxic 
capacity and a decreased cytokine production, which is a result of secreted 
factors by the tumor cells and the TME [159]. For example, overexpression of 
TGFβ can suppress CD16-mediated IFNγ production [213]. Moreover, together 
with IL-10, it inhibits the cytotoxic capacity and cytokine release of NK cells 
through downregulation of activating receptors, such as 2B4, NKp30 and 
DNAM-1 [36] [83] [159]. Macrophage migration inhibitory factor (MIF) has been 
shown to negatively correlate with the RFS [221] and it leads to a downregulation 
of NKG2D [111].  
In order to restore NK cell function, various therapeutical options are being tested. 
The first option is to boost the effector function of NK cells by treatment with 
cytokines. As one example, the effect of IL-15 is elucidated in the clinic. IL-15 is 
less toxic than IL-2, but the dose required shows severe side effects. Therefore, 
IL-15 “superagonists” are developed, which exhibit an increased in vivo half-life 
and reduced toxicity [81] [159]. An example of an IL-15 “superagonist” is 
ALT-803, which has been shown to increase the degranulation and IFNγ release 
of NK cells [66] [92]. The use of ALT-803 is currently tested in clinical trials [185].  
Furthermore, checkpoint inhibitors, such as anti-PD-1, are used to restore not 
only T cell function but also NK cell function [159]. Nevertheless, the outcome 
was disappointing so far, since only 11-24 % of the patients responded to the 
treatment [64]. Clinical trials are currently testing the combined treatment of anti-
PD-1 with anti-NKG2A (monalizumab) antibody, anti-KIR2D antibody (lirilumab) 
or anti-TIGIT (BMS-986207) antibody. The idea behind this co-treatment is to 
restore the effector functions of NK cells and T cells [6] [159] [201]. 
Finally, adoptive NK cell transfer is investigated as a treatment option. For this, 
modified cell lines, such as NK92, or NK cells from third-party donors that have 
been expanded ex vivo can be used. Moreover, the use of engineered NK cells, 
so-called chimeric antigen receptor (CAR)-NK cells, are currently evaluated. Like 
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CAR-T cells, they can target a specific antigen, but they show a lower risk of long-
term toxicity and autoimmunity, probably due to the relatively short lifespan of 
CAR-NK cells. Moreover, they should not cause graft-versus-host disease 
(GVHD) [159] [148]. Currently, CAR-NK cells are analyzed targeting CD24 (a 
stem-cell marker) [109] and mesothelin (the receptor for CA-125) [126]. CA-125 
seems a promising target since it is overexpressed in over 80 % of ovarian cancer 
patients [95]. 
Conclusively, NK cells are able to recognize and kill malignant cells. However, 
their effector function in various cancers is impaired. Therefore, different 
approaches to restore the NK cell effector functions are tested in the clinic, such 
as activation with cytokines, usage of checkpoint inhibitors (e.g. anti-PD-1) or 
adoptive NK cell transfer. Nevertheless, the results are still disappointing. Thus, 
the medical need to detect novel mechanisms to reactivate NK cells is strong. 
1.3 The Hippo pathway and its role in cancer 
In ovarian cancer, many pathways are dysregulated and one of them is the Hippo 
pathway [97] [205] [250]. This thesis provides evidence that components of the 
Hippo pathway are dysregulated in tumor-associated NK cells of ovarian cancer 
patients, but their functions are potentially Hippo-independent. 
The Hippo pathway is responsible for the control of organ size, but its 
dysregulation also plays a role in tumor development [60]. It is dysregulated at 
high frequency in a broad range of cancers, such as lung cancer, colorectal 
cancer, ductal carcinoma and ovarian cancer [205], correlating with a poor 
prognosis in most of the cases [82] [236] [250].  
The Hippo signaling pathway consists of a cascade of multiple serine/threonine 
kinases and is regulated by contact inhibition, cell-cell adhesion, apicobasal 
polarity, and mechanotransduction. It can be activated by LPA and sphingosine-
1-phosphate (S1P) through their engagement to the G protein-coupled receptors 
(GPCRs) – LPA receptors (LPAR) and S1P receptors (S1PR) [88]. 
When the Hippo pathway is turned on, mammalian STE20-like protein kinase 
(MST) 1 and MST2 are activated and recruit the adaptor protein salvador 
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homologue 1 (SAV1), leading to the phosphorylation of large tumor suppressor 
(LATS) 1 and LATS2 [42]. Moreover, LATS1 and LATS2 can also be activated 
by MOB kinase activator 1 (MOB1, encoded by MOB1A and MOB1B) [48] [91] 
(see Introductory Fig. 3). Next, yes-associated protein (YAP, encoded by YAP1) 
and transcriptional co-activator with PDZ-binding motif (TAZ, also known as 
WWTR1) are phosphorylated by LATS1 and LATS2 at Ser 127 [87] [120] [253]. 
Then, the 14-3-3 protein can bind to phosphorylated YAP and TAZ, sequestering 
them in the cytoplasm [251]. In addition, YAP and TAZ can be further 
phosphorylated at Ser 381, marking them for ubiquitination by SCFβ-TRCP E3 
ubiquitin ligase and ubiquitin-mediated degradation [253] (Introductory Fig. 3).  
Introductory Fig. 3: “ON-state” of the Hippo pathway. 
MST1/2 phosphorylates and recruits SAV1 and then phosphorylates LATS1/2 and MOB1. 
LATS1/2 then phosphorylate YAP to which 14-3-3 can bind, leading to cytoplasmic retention of 
YAP. TEAD no longer binds to the DNA and hence, does not induce Hippo target gene 
transcription. YAP1 can be further phosphorylated marking it for ubiquitination by the E3 ubiquitin 
ligase SCFβ-TRCP. Finally, YAP is proteasomally degraded.  
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Conversely, when the Hippo pathway is turned off, YAP and TAZ are not 
phosphorylated and can translocate into the nucleus where they bind to the TEA 
domain transcription factors (TEADs) and activate the transcription of target 
genes [252]. The target genes are involved in cell survival, proliferation and 
migration, for example, connective tissue growth factor (CTGF) [252], 
angiomotin-like protein 2 (AMOTL2) [55] and amphiregulin (AREG) [245] 
(Introductory Fig. 4). Besides, AMOTL2 has been shown to inhibit YAP as a 
negative feedback loop [55] [254]. 
Introductory Fig. 4: “OFF-state” of the Hippo pathway. 
If MST1/2 are not activated, LATS1/2 are not phosphorylated and cannot phosphorylate YAP in 
turn. Hence, YAP translocates into the nucleus, binds to TEAD and activates the transcription of 
the Hippo target genes CTGF, AREG, and AMOTL2.  
YAP is frequently amplified or overexpressed in human tumors and epigenetic 
silencing of MST1, MST2, LATS1, and LATS2 have been commonly reported 
[88]. It has been described that YAP is located within the nucleus in 14 % of 
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ovarian cancer cases and increased nuclear location of YAP is associated with a 
poor prognosis. Furthermore, YAP overexpression can transmit chemoresistance 
in ovarian cancer [250]. In small cell lung cancer (SCLC), WW domain binding 
protein 5 (WBP5) was shown to induce the nuclear accumulation of YAP1, 
probably through the inhibition of MST1/2 and thereby inducing multidrug 
resistance and decreased apoptosis [210]. In addition, it was demonstrated that 
S1P as well as LPA turn off the Hippo pathway and thereby reduce the 
phosphorylation of YAP in ovarian cancer cells [33] [65]. Moreover, the YAP-
TEAD complex in ovarian cancer cells can be suppressed by usage of 
verteporfin, which inhibits the interaction of YAP with TEAD [67]. 
Expression-profiling studies have demonstrated that YAP, TAZ and TEAD 
transcription factors are expressed in multiple types of stem cells and that YAP 
plays a role in maintaining stem cell pluripotency [127] [178] [216]. Hence, 
hyperactivity of YAP and TEAD may influence tumor growth by conveying stem 
cell properties [88].  
Taken together, the Hippo pathway is dysregulated in a broad range of tumor 
entities. Here, mutations in MST1/2 and LATS1/2 are found, while YAP is 
amplified and located in the nucleus. YAP overexpression can transmit 
chemoresistance and high nuclear location of YAP was associated with a poor 
prognosis. In the nucleus, YAP forms a complex with TEAD to induce Hippo 
target gene transcription.  
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1.3.1 The Hippo pathway protein TEAD and its coactivators  
In mammals, four TEADs exist (TEAD1-4) [128]. Due to their important function 
during embryonic development, TEAD1 and TEAD4 knockouts are embryonically 
lethal in mice [45] [237].  
At the N-terminus, TEADs contain a TEA/ATTS domain, necessary to bind to 
DNA as a homeodomain. This domain is highly conserved among the TEAD 
family members and recognizes the sequence motif 5′-GGAATG-3′ [128]. It was 
shown that mutations of Ser 100 and Gln 103 residues completely block binding 
of TEAD4 to the DNA [194]. Furthermore, at the C-terminus, TEADs have a 
transactivation domain, which binds to coactivators and is needed to induce 
target gene transcription. This domain is also highly conserved [128].  
TEADs are mainly known to interact with their coactivators YAP and TAZ to 
induce transcription of Hippo target genes. However, they can also bind to 
vestigial-like (VGLL) proteins. This family consists of four family members – 
VGLL1-4. VGLLs share the same binding sites on TEADs as YAP and TAZ and 
therefore compete with them for TEAD binding [128]. For example, if VGLL4 
binds to TEAD, it inhibits the target gene expression of YAP/TAZ-TEAD and 
therefore inhibits tumor growth [248]. Strikingly, overexpression of VGLL1 
upregulates insulin-like growth factor binding protein-5 (IGFBP-5) expression and 
facilitates cell growth, like the YAP/TAZ-TEAD4 complex [171].  
However, TEAD not only induces the transcription of Hippo target genes, but it 
was also described that TEAD4 plays a role in the regulation of the Wnt/β-catenin 
signaling. Here, TEAD4 directly interacts with transcription factor 4 (TCF4) to 
promote TCF4 transactivation and thereby the expression of Wnt target genes. 
VGLL4 inhibits TEAD4-TCF4 binding, although it does not compete with TCF4 
for TEAD binding. It rather represses the TEAD4-TCF4 target gene expression, 
by a conformational change of the TEAD4-TCF4-VGLL4 complex [99].  
Another coactivator family that binds to TEADs is the p160 family of steroid 
receptors which was identified using yeast-two hybrid screens in which the 
domain of steroid receptor coactivator 1 (SRC1) bound to TEAD [12].  
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In several cancers, high expression of TEADs was observed and is associated 
with poor clinical outcomes. For example, TEAD1 expression was increased in 
prostate cancer [110], while the expression of TEAD4 was increased in breast 
cancer [84] [223], head and neck squamous cell carcinoma (HNSCC) [249], and 
metastatic melanoma [146]. In colorectal cancer, TEAD4 was mainly expressed 
in the metastatic tissue and a knockout of TEAD4 decreased cell migration and 
metastasis in vitro and in vivo. Interestingly, this effect seemed to be 
YAP-independent as the metastatic potential could be restored with a 
YAP-binding-deficient Y429H TEAD4 mutant [133]. 
Summing up, TEADs mainly interact with their coactivators YAP and TAZ, but 
can also bind to VGLL and p160 proteins. VGLLs and YAP/TAZ share the same 
binding site on TEAD and therefore compete for TEAD binding. TEADs are 
frequently upregulated in various cancers and are associated with a poor clinical 
outcome. Nevertheless, TEAD do not only play a role in the Hippo pathway, but 
also in other pathways, such as the Wnt/β-catenin signaling pathway.  
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1.3.2 Hippo signaling and immune cells 
The Hippo pathway in cancer is mainly known for its role in tumor cells. However, 
it has been described to play a role in modulating immune cell responses, too. 
YAP can induce the expression of cytokines in tumor cells, which modify the TME. 
Wang et al. showed that YAP1-driven CXCL5 secretion led to the recruitment of 
C-X-C motif chemokine receptor 2 (CXCR2)-expressing MDSCs. Furthermore, 
blocking of the CXCL5-CXCR2-axis led to an inhibited tumor progression [224]. 
In a mouse model for HGSOC, it was demonstrated, that YAP1 is downstream of 
the oncogene protein kinase C iota (PRKCI) and induces TNFα expression, which 
recruits MDSCs and suppresses CTLs and thereby promotes tumor growth [190]. 
Moreover, TAM polarization towards an immunosuppressive M2-phenotype was 
induced by YAP1-expressing colon cancer cells, but not if YAP1 was knocked out 
in these cells [93]. It was reported that YAP and TAZ enhance the expression of 
programmed death-ligand 1 (PD-L1) in breast and lung cancer cell lines which 
represses T cell function, while the expression of MST1/1 and LATS1/2 inhibited 
the expression of PD-L1 [96]. Further, binding of YAP1 to the PD-L1 promoter in 
lung adenocarcinoma cells [117] and to the PD-L1 enhancer in melanoma cells 
was revealed [106]. Conversely, a double knockout of LATS1/2 was highly 
tumorigenic in vitro, but surprisingly poorly tumorigenic in vivo. This can be 
explained by the secretion of EVs by the double knockout cells, which bind to toll-
like receptors (TLRs) and thereby inducing a type I IFN response. This provokes 
CTL clonal expansion and maturation of DCs and hence mediates tumor 
destruction [156]. 
So far, little is known about the intrinsic function of the Hippo pathway in immune 
cells. It is known that MST1 regulates the transcription factor TEAD2, which then 
binds to the consensus motif in the 3′ untranslated region of CD19 and hence 
induces the expression of CD19 in murine B cells [9].  
MST1-deficiency in T cells leads to a reduced expression of forkhead box O1 
(FOXO1), the IL-7 receptor, and B-cell lymphoma 2 (BCL2), while FAS was 
upregulated. In this state of immunodeficiency, naïve T cells were lost due to the 
MST1/FOXO induced apoptosis of the cells [158]. Moreover, Mst1−/− CTLs 
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depicted an increased T-box transcription factor 21 (T-bet) expression, 
associated with enhanced levels of IFNγ and granzyme B. These Mst1−/− CTLs 
were able to suppress tumor growth in a mouse lymphoma (E.G7-OVA) tumor 
model [239].  
Furthermore, YAP is highly expressed in Tregs and facilitates FOXP3 expression 
and Treg function in vitro and in vivo [160]. TAZ expression in CD4+ T cells 
promotes the Th17 differentiation and dampens the Treg differentiation, while 
TEAD1 overexpression induced Treg differentiation [76].  
Activation of CD8+ T cells by antigen-stimulation together with IL-2 induces the 
expression of Hippo pathway components (such as SAV1, LATS1, MOB1, 
TEAD1, and TEAD3), resulting in YAP degradation and Blimp-1 expression, 
which is required for terminal differentiation of the T cells [211].  
YAP also plays a role in the antiviral response of macrophages. TANK-binding 
kinase 1 (TBK1) is activated by viral DNA or RNA and further activates the 
transcription factor interferon regulatory factor 3 (IRF3) by phosphorylation of 
IRF3. IRF3 then induces a type I IFN response [147]. However, YAP can bind to 
IRF3 and prohibit its dimerization and translocation to the nucleus and hence, 
block the antiviral immune response. Though, YAP can be phosphorylated by the 
inhibitor of nuclear factor κ-B kinase subunit epsilon (IKKɛ) at Ser 403 leading to 
degradation of YAP in lysosomes [225].  
So far, nothing is known about the expression of the Hippo pathway in NK cells. 
Nevertheless, in natural killer T-cell lymphoma (NKTCL) tissue and cell lines, it 
was described, that MST1 was downregulated, while YAP was upregulated [43]. 
Taken together, the Hippo pathway not only plays a pivotal role in tumor cells but 
also has an impact on immune cells. Driven through the Hippo pathway, tumor 
cells can secret immunosuppressive cytokines, can upregulate PD-L1 to inhibit 
CTLs, or recruit tumor-promoting MDSCs and TAMs. However, little is known 
about the intrinsic function of the Hippo pathway in immune cells. 
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1.4 Aims of this thesis 
Ovarian cancer has the highest mortality rate of all gynecological cancers 
worldwide. However, the therapeutic options within the last thirty years have not 
improved and the overall perspective of the patients is disappointing. As part of 
the innate immune system, NK cells play a crucial role in the recognition and 
elimination of malignant cells. The aim of this study was to characterize molecular 
and phenotypical alterations of TANKs, leading to dysregulation of NK cell 
effector function. Unraveling dysregulations of TANKs is essential to identify 
novel therapeutic options to restore impaired effector functions and immune 
surveillance. Furthermore, the crosstalk between NK cells and TAMs was 
investigated. To this end, the following specific questions were addressed: 
1. What is the function of sNKG2D-Ls? 
a. Do soluble NKG2D-Ls influence NK cells, TAMs or the crosstalk 
between these two? 
b. What are the specific target genes of membrane-bound NKG2D-Ls 
vs. soluble NKG2D-Ls when engaged to the NKG2D receptor? 
2. What are the molecular and functional alterations of TANKs and which 
factors are responsible for these changes? 
a. Which receptors are expressed on the surface? Do they show signs 
of exhaustion? 
b. What is the cytotoxic potential of patient-derived NK cells and which 
receptors are important for the recognition of ovarian cancer cells? 
c. Which factor within the ascites is responsible for the reduced 
DNAM-1 expression? 
3. What are the molecular mechanisms directing a tumor-associated NK cell 
phenotype? 
a. Which signaling pathways are dysregulated in patient-derived NK 
cells? 
b. What induces the expression of the Hippo pathway component 
TEAD4 in healthy donor-derived NK cells and which function do 
TEAD4-expressing NK cells display? 
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2 Material and Methods 
2.1 Material 
2.1.1 Solutions, chemicals, and buffers 
Table 2: Solutions, chemicals, and buffers. 
Solutions/chemicals/buffers Supplier/composition 
7-AAD Viability Staining 
Solution 
Biolegend, Koblenz 
Absolute qPCR SYBR Green 
Mix 
Thermo Fisher Scientific/Life Technologies, 
Darmstadt 
Accutase Sigma-Aldrich, Steinheim 
Aqua ad iniectabilia Braun, Melsungen 
Annexin V Binding Buffer, 10x 
Concentrate 
BD, Heidelberg 
Blasticidin S HCl Fisher Scientific, Schwerte 
Blotting Buffer, 1x 25 mM Tris-HCL, 192 mM Glycine, 20 % (v/v) 
MeOH 
CellTracker™ Violet BMQC Invitrogen/Life Technologies/Thermo Fisher 
Scientific, Darmstadt 
Coating buffer, 1x 100 mM NaHCO3, 33.5 mM Na2CO3, pH 9.5 
DPBS, without calcium and 
magnesium 
Thermo Fisher Scientific/Life Technologies, 
Darmstadt 
Dynabeads human T-
Activator CD3/CD28 
Thermo Fisher Scientific/Life Technologies, 
Darmstadt; 
dissolved in PBS with 0.1 % (w/v) BSA 
RBC lysis buffer 155 mM NH4Cl, 10 mM KHCO3, 0.1 mM 
EDTA pH 7.2-7.4 
Ethanol Roth, Karlsruhe 
FACS buffer PBS, 0.2 % (w/v) BSA, 0.2 % (w/v) sodium 
azide 
FACS Clean solution BD, Heidelberg 
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FACS Flow BD, Heidelberg 
FACS Rinse solution BD, Heidelberg 
FACS Shutdown solution BD, Heidelberg 
FastDigest Buffer, 10x Thermo Fisher Scientific/Life Technologies, 
Darmstadt 
FBS  Thermo Fisher Scientific/ Life Technologies, 
Darmstadt 
Sigma-Aldrich, Steinheim 
Ficoll (LSM 1077, 
Lymphocyte Separation 
Medium) 
Capricorn Scientific, Ebsdorfergrund 
Human AB serum Sigma-Aldrich, Steinheim 
Immobilon Forte Western 
HRP Substrate 
Merck Millipore, Darmstadt 
Isopropanol Carl Roth, Karlsruhe 
LB medium 1 % (w/v) Peptone, 1 % (w/v) NaCl, 0.5 % 
(w/v) Yeast extract 
MACS buffer PBS, 0.5 % (v/v) FBS, 2 mM EDTA, pH 7.2 
Monensin solution (1000x) Biolegend, Koblenz 
PBS 137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 
2 mM KH2PO4, pH 7.4 
peqGOLD TriFast VWR, Darmstadt 
Penicillin Streptomycin 
solution (100x) 
10000 U/ml Penicillin, 10000 μg/ml 
Streptomycin 
Sigma-Aldrich, Steinheim 
Phosphatase Inhibitor 
Cocktail 
100 mM NaPP, 100 mM ß-glycerophosphate, 
100 mM Na3VO4, 100 mM NaF 
Protease Inhibitor Cocktail Sigma-Aldrich, Steinheim 
RIPA buffer 50 mM Tris-HCL pH 8.0, 150 mM NaCl, 0.1% 
SDS (w/v), 0.5 % (v/v) TritonX-100, 0.5 % 
(w/v) DOC (Deoxycholic acid) 
RPMI 1640 with 
GLUTAMAX-I  
RPMI 1640 with GLUTAMAX-I + 5 % (v/v) 
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(R5 medium macrophages) human AB serum + 1 % (v/v) sodium pyruvate 
RPMI 1640 with 
GLUTAMAX-I 
Thermo Fisher Scientific/Life Technologies, 
Darmstadt 
Schneider's Drosophila 
Medium 
Thermo Fisher Scientific/Life Technologies, 
Darmstadt 
+ 10 % (v/v) FBS + 1 % (v/v) 
Penicillin/Streptomycin  
SDS running buffer, 1x 25 mM Tris-HCL, 192 mM Glycine, 0.1 % (w/v) 
SDS, pH 8.3 
Sodium pyruvate solution 
(100 mM) 
Sigma-Aldrich, Steinheim 
TBS-T 
150 mM NaCl, 50 mM Tris-HCl, 0.1 % (v/v) 
Tween-20, pH 7.5 
Trypan Blue Solution, 0.4 % Gibco/Life Technologies/Thermo Fisher 
Scientific, Darmstadt 
Trypsin-EDTA Solution, 10x Sigma-Aldrich, Steinheim 
Tween20 Applichem, Darmstadt 
All chemicals were purchased from Merck or Carl Roth, if not stated otherwise. 
2.1.2 Cytokines, inhibitors, and proteins 
Table 3: Cytokines, inhibitors, and proteins. 
Cytokine/inhibitor/protein Supplier 
FastDigest EcoRI Thermo Fisher Scientific/Life 
Technologies, Darmstadt 
FastDigest XhoI Thermo Fisher Scientific/Life 
Technologies, Darmstadt 
LPS (100 ng/ml) of E.coli 0111:B4 L4391 Sigma-Aldrich, Steinheim 
Recombinant human, Interleukin-2  
(rhuIL-2, 11340025, 200 U/ml or 10 U/ml)  
Immunotools , Friesoythe 
Recombinant human, Interleukin-15  
(rhuIL-15, 11340153, 10 ng/ml)  
Immunotools , Friesoythe 
Recombinant human, ULBP2-His 
(12143-H08H-100, 200 nM) 
Sino Biological, Eschborn 
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SB-431542 (TGFβ receptor kinase inhibitor, 
13031, 10 µM) 
Cayman chemical/Biomol, 
Hamburg 
T4 Ligase Thermo Fisher Scientific/Life 
Technologies, Darmstadt 
TGF-β1, human platelets (616450-1UG, 
5 ng/ml) 
Merck, Darmstadt 
YAP-TEAD inhibitor 1 (Peptide 17) 
(SEL-S8164-1MG, 40 nM) 
Selleckchem/Biozol, Eching 
 
2.1.3 Vectors 
Table 4: Vectors. 
Vector Function 
pAc5.1/V5-His Expression plasmid for S2 cells 
pAc5.1_ULBP2 Overexpression of human ULBP2 in S2 cells 
pCoBlast Plasmid carrying Blasticidin resistance  
 
2.1.4 Kits 
Table 5: Kits. 
Kit name Supplier 
Calcium Phosphate 
Transfection Kit 
Thermo Fisher Scientific/Life Technologies, 
Darmstadt 
DNA-free™ DNA Removal Kit Invitrogen/ Life Technologies, Darmstadt 
Human IFN-γ ELISA MAX™ 
Standard  
Biolegend, Koblenz 
NK Cell Isolation Kit, human Miltenyi Biotec, Bergisch Gladbach 
PierceTM BCA protein assay Kit Thermo Fisher Scientific, Darmstadt 
RevertAid RT Reverse 
Transcription Kit + Oligo(dT)18 
primers 
Thermo Fisher Scientific, Darmstadt 
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2.1.5 Antibodies and immunoglobulins 
Table 6: Antibodies and immunoglobulins. 
Antigen Label Isotype Species Application 
and 
concentration 
Supplier Clone Order 
no. 
Actin HRP IgG Goat WB; 20 ng/ml SCBT, 
Heidelber
g 
- sc-
1616 
Annexin 
V 
AF647 - Human FACS; 50 ng Biolegend, 
Koblenz, 
Koblenz 
- 64091
2 
Anti-
human 
IgG Fc 
AF647 IgG2a Mouse FACS; 300 ng Biolegend, 
Koblenz 
HP60
17 
40932
0 
Anti- 
mouse 
IgG 
FITC IgG Goat FACS; 250 ng Biolegend, 
Koblenz 
- 40530
5 
Anti-
mouse 
IgG 
HRP - Horse WB; 15.3 
ng/ml 
CST, 
Frankfurt 
- 7076
S 
Anti-
rabbit 
IgG 
HRP - Goat WB; 9.2 ng/ml CST, 
Frankfurt 
- 7074
S 
CCR7 PE IgG2a Rat FACS; 1 µg BD, 
Heidelber
g 
3D12 55217
6 
CD3 V500 IgG1κ Mouse FACS; 50 ng BD, 
Heidelber
g 
UCHT
1 
56141
7 
CD8 APC IgG1κ Mouse FACS; 25 ng Biolegend, 
Koblenz 
SK1 34472
1 
CD8 PerCP-
Cy5.5 
IgG1κ Mouse FACS; 250 ng Biolegend, 
Koblenz 
SK1 34470
9 
CD16 - IgG1κ Mouse Blocking; 10 
µg/ml 
Biolegend, 
Koblenz 
3G8 30201
4 
CD16 APC-
Cy7 
IgG1κ Mouse FACS; 100 ng Biolegend, 
Koblenz 
3G8 30201
8 
CD45-
RA 
APC IgG2b Mouse FACS; 11.2 ng eBioscien
ce/Invitrog
en/ 
HI100 17-
0458-
42 
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Thermo 
Fisher 
Scientific, 
Darmstadt 
CD56 BV421 IgG1κ Mouse FACS; 60 ng Biolegend, 
Koblenz 
HCD5
6 
31832
8 
CD56 FITC IgG1κ Mouse FACS; 50 ng eBioscien
ce/Invitrog
en/ 
Thermo 
Fisher 
Scientific, 
Darmstadt 
TULY
56 
11056
642 
CD56 PerCP-
Cy5.5 
IgG1κ Mouse FACS; 150 ng Biolegend, 
Koblenz 
5.1H1
1 
36250
6 
CD69 PE-Cy7 IgG1κ Mouse FACS; 50 ng Biolegend, 
Koblenz 
FN50 31091
2 
CD107a PE IgG1κ Mouse FACS; 400 ng Biolegend, 
Koblenz 
H4A3 32860
8 
CD158a 
(KIR2DL
1) 
BV421 IgM Mouse FACS; 125 ng BD, 
Heidelber
g 
HP-
3E4 
56431
8 
CD158b 
(KIR2DL
2/3) 
BB515 IgG2b Mouse FACS; 50 ng BD, 
Heidelber
g 
CH-L 56467
8 
CD158e 
(KIR3DL
1) 
APC IgG1κ Mouse FACS; 12.5 ng BD, 
Heidelber
g 
DX9 56410
3 
CD159a 
(NKG2A) 
APC REA 
Control 
Recombi
nant 
human 
FACS; 0.5 µl Miltenyi 
Biotec, 
Bergisch 
Gladbach 
 130-
098-
809 
CD159c 
(NKG2C
) 
PE-
Vio770 
REA 
Control 
Recombi
nant 
human 
FACS; 1 µl Miltenyi 
Biotec, 
Bergisch 
Gladbach 
 130-
103-
702 
DNAM-1 - IgG1κ Mouse Blocking; 10 
µg/ml 
Miltenyi 
Biotec, 
Bergisch 
Gladbach 
DX11 130-
092-
479 
DNAM-1 FITC IgG1κ Mouse FACS; 62.5 ng BD, 
Heidelber
g 
DX11 55978
8 
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DNAM-1 PE-Cy7 IgG1κ Mouse FACS; 200 ng Biolegend, 
Koblenz 
11A8 33831
5 
IgG1κ - IgG1κ Mouse Blocking, 
Crosslink.;10 
µg/ml 
Biolegend, 
Koblenz 
MOP
C-21 
40010
2 
rhIgG1-
Fc 
- - Human FACS; 500 ng R&D/Bio-
Techne, 
Wiesbade
n 
- 110-
HG-
100 
Recombi
nant 
human 
IgG 
(REA 
Control 
(S)) 
APC  Human FACS; 0.5 µl Miltenyi 
Biotec, 
Bergisch 
Gladbach 
REA2
93 
130-
104-
614 
Recombi
nant 
human 
IgG 
(REA 
Control 
(S)) 
PE-
Vio770 
 Human FACS; 1 µl Miltenyi 
Biotec, 
Bergisch 
Gladbach 
REA2
93 
130-
104-
616 
Mouse 
Gamma 
Globulin 
-  Mouse FACS; 5.8 µg Jackson 
ImmunoR
esearch 
Europe 
Ltd, USA 
 015-
000-
002 
MICA/B AF647 IgG2a Mouse FACS; 100 ng Biolegend, 
Koblenz 
6D4 32091
4 
NCOA1 - IgG1 Mouse WB; 0.2 µg/ml SCBT, 
Heidelber
g 
1135/
H4 
sc-
32789 
NKG2D - IgG1κ Mouse Blocking; 10 
µg/ml 
Biolegend, 
Koblenz 
1D11 32080
2 
NKG2D FITC IgG1κ Mouse FACS; 100 ng Biolegend, 
Koblenz 
1D11 32082
0 
rhNKG2
D-FC 
- - Human FACS; 500 ng R&D/Bio-
Techne, 
Wiesbade
n 
- 1299-
NK-
050 
NKp30 Purified IgG1κ Mouse Blocking; 10 
µg/ml 
Biolegend, 
Koblenz 
p30-
15 
32520
4 
Material and Methods  41 
 
NKp30 BV421 IgG1κ Mouse FACS; 125 ng BD, 
Heidelber
g 
p30-
15 
56338
5 
NKp44 AF647 IgG1κ Mouse FACS; 25 ng Biolegend, 
Koblenz 
P44-8 32511
2 
NKp46 AF647 IgG1κ Mouse FACS; 25 ng Biolegend, 
Koblenz 
9E2 33191
0 
NKp46 PE IgG1κ Mouse FACS; 25 ng Biolegend, 
Koblenz 
9E2 33190
8 
NKp46 PE-Cy7 IgG1κ Mouse FACS; 25 ng Biolegend, 
Koblenz 
9E2 33191
6 
PD-1 PE IgG1κ Mouse FACS; 50 ng Biolegend, 
Koblenz 
EH12.
2H7 
32990
6 
pERK1/2 - IgG2a Mouse WB; 200 ng/ml SCBT, 
Heidelber
g 
E-4 sc-
7383 
pYAP1 
(Ser 
127) 
- - Rabbit WB; 184 ng/ml CST, 
Frankfurt 
- 4911 
TEAD4 - - Rabbit WB; 5.25 
µg/ml 
Abcam, 
Berlin 
- ab974
60 
TGF-
beta 1, 
2, 3 
- IgG1 Mouse Blocking; 5 
µg/ml 
R&D/Bio-
Techne, 
Wiesbade
n 
1D11 MAB1
835-
SP 
TIM-3 BV421 IgG1κ Mouse FACS; 100 ng Biolegend, 
Koblenz 
F38-
2E2 
34500
8 
TIGIT APC IgG2a Mouse FACS; 30 ng Biolegend, 
Koblenz 
A151
53G 
37270
6 
ULBP2 - IgG1 Mouse FACS; 250 ng BamOma
B 
BUM
O1 
BUM
O1-
100 
ULBP2 PE IgG2a Mouse FACS; 5 ng R&D/Bio-
Techne, 
Wiesbade
n 
16590
3 
FAB1
298P 
Suitable isotype controls were purchased at Biolegend or BD Bioscience. 
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2.1.6 qRT-PCR oligonucleotides 
Oligonucleotides were purchased from the company Sigma-Aldrich and were 
dissolved with ddH2O at a concentration of 100 pmol/µl.  
Table 7: Transcript name and sequence of qRT-PCR oligonucleotides. 
Transcript Sequence (5’  3’)  
hACOD1_qfor 
hACOD1_qrev 
ATATGCTGCTTTTGTGAACGGTG 
GCTAAAGCTGTGAGGACAGGAA 
hAMOTL2_qfor 
hAMOTL2_qrev 
GACAGCCTTCTGGGGTGCAGCAGTA 
GCTCAGAGTCCTGAAGCACCACCTCCT 
hAREG_qfor 
hAREG_qrev 
ACTCGGCTCAGGCCATTATGCTGCT 
TGTGGTCCCCAGAAAATGGTTCACG 
hC2_qfor 
hC2_qrev 
CCTGAACATCAACCAGAAGAGGA 
CTCACCATCCTTCTTGGACCC 
hC3_qfor 
hC3_qrev 
CGGATCTTCACCGTCAACCA 
GCTGGTTCTGAGAAGACAAGGA 
hCD226_qfor 
hCD226_qrev 
TACCCACAGGGAACTTGGCA 
GTGGCTATTTGATGGCACAGC 
hCFB_qfor 
hCFB_qrev 
CAACTTCACAGGAGCCAAAAAGT 
AAACCATGCCACAGAGACTCA 
hCFI_qfor 
hCFI_qrev 
GTCCCCTGGTCTCCTTACCT 
ACCCCACTGAAGTGAAAAGACTC 
hCLEC4E_qfor 
hCLEC4E_qrev 
TTTCACAGAGCTCTCCTGCTAC 
GCCCAGGAAATGGTGTCAGTA 
hCTGF_qfor 
hCTGF_qrev 
TGCGAAGCTGACCTGGAAGAGAACA 
TCGGCCGTCGGTACATACTCCACA 
hFCGR3A_qfor 
hFCGR3A_qrev 
AAGGAAATTGGTGGGTGACAGA 
GGTCTTCCTCCTTGAACACCC 
hGAPDH_qfor 
hGAPDH_qrev 
GGAAGGTGAAGGTCGGAGTC 
TGAAGGGGTCATTGATGGCA 
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hHLA-E_qfor 
hHLA-E_qrev 
GGCTCAGATCTCCGAGCAAA 
AGTAGCTCCCTCCTTTTCCAC 
hKLRK1_qfor 
hKLRK1_qrev 
AGCCATGGGAATCCGTTTCA 
AGGACATGGGCCACAGTAAC 
hMICA_qfor 
hMICA_qrev 
CTGCAGGAACTACGGCGATA 
CCCTCTGAGGCCTCGCT 
hMICB_qfor 
hMICB_qrev 
AGAAGAAAACATCAGCGGCAG 
CATCCCTGTGGTCTCCTGTC 
hNCOA1_qfor 
hNCOA1_qrev 
GCTACCCTCTGGAACTCAAGATT 
GATGAACTGTCCCCGAGGC 
hPLA2G7_qfor 
hPLA2G7_qrev 
GTGGTTTATCCTTTTGACTGGCA 
AGCAGCCATCAGTACTTGTATTTTG 
hRPL27_qfor 
hRPL27_qrev 
AAAGCTGTCATCGTGAAGAAC 
GCTGTCACTTTGCGGGGGTAG 
hTBX21_qfor 
hTBX21_qrev 
CCACCTGTTGTGGTCCAAGT 
CCCGGCCACAGTAAATGACA 
hTEAD1_qfor 
hTEAD1_qrev 
GCCCTGGCTATCTATCCACC 
CGTCTTGCCTGTCCTGAGTT 
hTEAD2_qfor 
hTEAD2_qrev 
GTTTTGGTCTGGAGGATCTGGG 
GAGGTCAGTAGATGGGGGAGT 
hTEAD3_qfor 
hTEAD3_qrev 
CGAAATGAGTTGATTGCACGC 
GCACCTTCTTCCGAGCTAGA 
hTEAD4_qfor 
hTEAD4_qrev 
GAGCTGATTGCCCGCTACAT 
TTTAGCTTGGCCTGGATCTCG 
hULBP2_qfor 
hULBP2_qrev 
GCCGCTACCAAGATCCTTCT 
GCAAAGAGAGTGAGGGTCGG 
hVAV1_qfor 
hVAV1_qrev 
CAGAGTATGACAAGCGCTGC 
GCAGGGGCTTCAAGAAATGC 
hVGLL1_qfor 
hVGLL1_qrev 
GTATCTCGTGGATCTGCCAGT 
CCAGTGGTTTGGTGGTGTAA 
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hYAP1_qfor 
hYAP1_qrev 
TGTCTTCTCCCGGGATGTCT 
CATCTCGAGAGTGATAGGTGCC 
hYY1_qfor 
hYY1_qrev 
CGGGCAACAAGAAGTGGGA 
TCAACCACTGTCTCATGGTCAATA 
2.1.7 Primary cells 
Healthy donor NK cells and monocytes were isolated from either buffy coats or 
LRS chambers from the University Hospital of Gießen and Marburg. When buffy 
coats were used, only female and age-matched donors were employed. Donors 
from LRS chambers were mainly male. Buffy coats were used in figures 1, 2, 3, 
6, 7, 8, 9 and 10. The remaining experiments were conducted with LRS 
chambers. For the experiment of table 1, the donors of the LRS chambers were 
female.  
Moreover, the TAMs and lymphocytes from ascites or peripheral blood, as well 
as the cell-free ascites of ovarian cancer patients from the university hospital of 
Gießen and Marburg was used. The study was approved by the institutional 
ethics committee (reference number AZ 205_10). 
2.1.8 Cell lines and competent cells 
Table 8: Cell lines and competent cells. 
 
Cell line/competent 
cells 
Origin Cultivation 
K562 Human chronic 
myelogenous leukemia cell 
line 
IMDM + 10 % (v/v) FBS + 1 % 
(v/v) P/S 
OVCAR-4 Human ovarian cancer cell 
line 
RPMI with GLUTAMAX-I + 
10 % (v/v) FBS + 1 % (v/v) P/S 
Schneider 2 (S2) 
cells 
Drosophila cell line derived 
from late-stage embryo 
Schneider’s Drosophila 
medium + 10 % (v/v) FBS + 
1 % (v/v) P/S 
XL-1 blue E.coli LB medium 
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2.1.9 Software 
For the analysis of flow cytometry data, FlowJo V10 was used. 
GraphPad Prism 7 was used to create the graphs and to calculate the p-values 
using paired or unpaired Student’s t-tests. Unpaired t-tests were performed 
without Welch’s corrections. ns, not significant (p ≥ 0.05), *p < 0.05, **p < 0.01, 
***p < 0.001; ****p ≤ 0.0001 
Finally, ImageJ and Microsoft Office 2013 were used.  
2.2 Methods 
2.2.1 Cell biological methods 
2.2.1.1 Cultivation of cells 
K562 cells were maintained in IMDM supplemented with 10 % (v/v) FBS and 
1 % (v/v) penicillin/streptomycin (P/S) solution, while OVCAR-4 cells were 
cultured in RPMI 1640 with GLUTAMAX-I + 10 % (v/v) FBS and 1 % (v/v) P/S. 
Depending on their growth rate, all cells were passaged two to three times per 
week. To detach OVCAR-4 trypsin was used. Drosophila Schneider 2 (S2) cells 
were maintained in Schneider’s Drosophila medium + 10 % (v/v) FBS and 
1 % (v/v) P/S and incubated at 27 °C without CO2. All cells were regularly tested 
for mycoplasma contamination by PCR and only mycoplasma-negative cells 
were used for the assays. Primary NK cells were cultured in IMDM supplemented 
with 10 % (v/v) FBS and 1 % (v/v) P/S at a cell density of 1*106/ml, while 
monocytes where differentiated into macrophages in RPMI 1640 with 
GLUTAMAX-I + 5 % (v/v) human AB serum + 1 % (v/v) sodium pyruvate without 
any addition of cytokines. Additionally, primary cells were cultivated in cell-free 
ascites from ovarian cancer patients as indicated. Besides S2 cells, all cells were 
maintained at 37 °C and 5 % CO2. 
2.2.1.2 Transfection and generation of S2 ULBP2 cells 
S2 cells were co-transfected with the expression vector pAc5.1/V5-His_ULBP2 
and the selection vector pCoBlast in a ratio of 19:1 using the calcium phosphate 
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transfection kit (Thermo Fisher Scientific) according to the manufacturer’s 
protocol. The cells were selected with 25 µg/ml Blasticidin for 2-3 weeks until the 
expression of ULBP2 reached almost 100 %.  
2.2.1.3 Isolation of PBMCs from buffy coats and LRS chambers 
In order to isolate the PBMCs from buffy coats and LRS chambers, ficoll density 
gradient centrifugation was performed. Monocytes were further purified from 
remaining cells by adherent cell positive selection. They were cultivated at least 
six days to generate monocyte-derived macrophages (MDMs). NK cells were 
negatively selected using the human NK cell isolation kit (Miltenyi Biotec). For 
resting NK cells, the cells were incubated with 10 U/ml IL-2 and for activated NK 
cells, they were stimulated with 200 U/ml IL-2 and 10 ng/ml IL-15 overnight.  
2.2.1.4 Processing of ascites and isolation of PBMCs from ascites  
Ascites samples of high grade serous ovarian carcinoma patients were provided 
by the University Hospital of Marburg. Included in the study are only patients, who 
did not receive treatment yet and who undergo first-line surgery. The study was 
approved by the institutional ethics committee (reference number AZ 205_10). 
Mononuclear cells were purified from the ascites using density gradient 
centrifugation. Cell-free ascites was generated by serial centrifugation.  
2.2.1.5 Treatment of macrophages 
Monocytes were differentiated at least six days into MDMs without the addition of 
cytokines. Then, MDMs were treated with 100 ng/ml LPS for the indicated time 
points.  
2.2.1.6 Antibody crosslinking 
For crosslinking, 10 µg/ml CD16 antibody or IgG control were added to 1x coating 
buffer. 100 µl of the mix were pipetted per well into a MaxiSorpTM 96-well-plate 
and incubated overnight at 4 °C. On the next day, the plate was washed twice 
with complete IMDM medium, followed by 30 minutes incubation with complete 
medium at room temperature for blocking of the plate. NK cells were seeded into 
the plate at a concentration of 1*106/ml for the indicated time points. For inhibitor 
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treatment, NK cells were pretreated with 40 nM P17 inhibitor for 30 minutes at 
room temperature, before the cells were seeded into the antibody-coated plate. 
The inhibitor was present throughout the whole duration of the assay.  
2.2.1.7 Flow cytometry 
MDMs were detached using accutase. Here, MDMs were incubated for at least 
30 minutes at 37 °C and then rinsed from the tissue culture plate. Suspension 
cells were washed with PBS and then stained. In general, cells were stained with 
fluorochrome-labeled antibodies for 30 minutes at 4 °C, before they were washed 
with FACS buffer and analyzed on a FACS Canto II cytometer (BD Bioscience). 
For staining with the NKG2D-FC recombinant receptor, cells were incubated for 
30 minutes at 4 °C with the recombinant receptor, washed with FACS buffer and 
then stained with an anti-human FC-AF647 antibody for another 30 minutes at 
4 °C, before the cells were analyzed. For the depicted MFI, the background 
geometric mean of the isotype was subtracted from the geometric mean of the 
specific staining of each sample. A list of antibodies used for flow cytometry is 
found in the materials section (see section 2.1.5). 
2.2.1.8 Killing assay 
NK cells were treated with 10 U/ml IL-2 to generate resting NK cells or stimulated 
with 200 U/ml IL-2 and 10 ng/ml IL-15 overnight to induce activation of NK cells. 
On the next day, for blocking experiments, NK cells were pretreated with 10 µg/ml 
blocking antibody or IgG control for 30 minutes at room temperature. Target cells 
were stained with 5 µM CellTracker™ Violet BMQC (Invitrogen) fluorescent dye 
in serum-free medium for 45 minutes at 37 °C. Then, cells were washed twice 
with complete medium. NK cells and target cells were seeded into a 96-well-plate 
with round bottom at the indicated effector to target (E:T) ratios. The plate was 
centrifuged at 100 g for one minute to bring cells into proximity and then incubated 
for three hours at 37 °C. Next, samples were washed with FACS buffer and 
stained with 50 ng 7-AAD solution, before they were analyzed on the FACS 
Canto II cytometer (BD Bioscience). 
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2.2.1.9 Degranulation assay 
NK cells were pre-treated like in the killing assay. NK cells and target cells were 
seeded into 96-well-plate with a round bottom at the indicated E:T ratios. The 
plate was centrifuged at 100 g for one minute to bring cells into proximity and 
then incubated for two hours at 37 °C. Then, 400 ng CD107a-PE and 2 µM 
Monensin (Biolegend) per well were added to the samples, followed by four hours 
of co-cultivation at 37 °C. Next, cells were washed with FACS buffer and stained 
with 60 ng CD56-BV421 or 25 ng NKp46-AF674 for 30 minutes at 4 °C. The cells 
were washed with FACS buffer and analyzed on the FACS Canto II cytometer 
(BD Bioscience). 
2.2.2 Molecular biological methods 
2.2.2.1 Cloning 
The pAc5.1/V5-His expression vector was used as a backbone, which contains 
an ampicillin resistance. The ULBP2 cDNA was ordered from IDT and was 
flanked by EcoRI and XhoI restriction sites. The vector and cDNA were digested 
with fast digest EcoRI and XhoI enzymes (Thermo Fisher Scientific) according to 
the manufacture’s protocol. Next, the digested vector and insert were ligated at a 
1:3 vector:insert ratio using T4 Ligase (Thermo Fisher Scientific) overnight at 
16 °C. 5 µl of the ligation mix was used for the transformation of XL1 blue 
competent bacteria. In brief, they were incubated at 42 °C for 90 seconds, 
followed by two minutes on ice, before they were recovered for 20 minutes in LB 
medium. Finally, they were spread on an agar plate containing ampicillin.  
2.2.2.2 RNA isolation and cDNA synthesis 
The cells were lysed in 1 ml TriFast and stored at -20 °C. In order to isolate the 
RNA, samples were thawed and 200 µl chloroform was added. The samples were 
mixed for 15 seconds by hand shaking and then incubated for two to three 
minutes at room temperature before they were centrifuged for 15 minutes at 
12,000 g and 4 °C. Next, the aqueous phase was transferred to a fresh tube, 
mixed with 500 µl isopropanol by vortexing and incubated for 10 minutes at room 
temperature. Afterward, the samples were centrifuged for 10 minutes at 12,000 g 
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and 4 °C. The supernatant was discarded and the RNA was washed with 1 ml 
70 % ethanol and centrifuged for 5 minutes at 7500 g and 4 °C. Finally, the 
supernatant was removed and the RNA pellet was air-dried for 5 minutes before 
it was resuspended in nuclease-free H2O. 
The cDNA synthesis was performed using the RevertAid RT Reverse 
Transcription Kit from Thermo Fisher Scientific according to the manufacturer’s 
protocol. Here, 1 µl Oligo (dT) 18 primers (Thermo Fisher Scientific) and 1 µl 
random hexamer primers were used. Between 100 and 500 ng RNA was 
transcribed and cDNA was diluted 1:5, 1:10 or 1:20 with nuclease-free H2O.  
2.2.2.3 RNA-seq and bioinformatics analysis  
RNA of the samples was isolated using the phenol-chloroform-extraction method 
described in the RNA isolation section (section 2.2.2.2). Possible DNA 
contamination was removed with the DNA-free™ DNA Removal Kit (Invitrogen) 
according to the manufacturer’s instructions. The quality of the RNA was verified 
using the Experion RNA StdSens Analysis Kit or using the Qubit fluorometer 
(Thermo Fisher Scientific). Next, RNA-libraries were generated from total RNA 
by using the TruSeq Stranded mRNA Library kit according to the manufacturer’s 
instructions. The sequencing was conducted on the Illumina HiSeq 1500 or HiSeq 
4000. A Run with 50 base single reads was performed.  
For the identification of NKG2D-Ls, sequencing was performed on an Illumina 
HiSeq 4000. Raw reads were aligned to the human and Drosophila genomes 
(retrieved from Ensembl 97) using STAR 2.6.1d. Reads aligning to the Drosophila 
genome were subtracted from the human alignment. Read counts were 
quantified in exonic regions of protein-coding transcripts and normalized to 
transcripts per million reads (TPM). Differential gene expression was assessed 
via edgeR (version 3.24.3) at a threshold of FDR ≤ 0.05 and |log2FC| ≥ 1. The 
samples were analyzed by the IKMB (University Kiel), and bioinformatics analysis 
was performed by Dr. Florian Finkernagel. 
For the comparison of differentially expressed genes of healthy donor NK cells 
vs. ascites-derived NK cells, raw reads were aligned to the human genome 
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(retrieved from Ensembl 92) using STAR 2.4.1a. RNA-seq data from healthy 
blood donors were obtained from the deposited data of Linsley et al. (E-GEOD-
60424) [129]. Read counts were quantified in exonic regions of protein-coding 
transcripts and normalized to TPM. Fold change of each gene was calculated by 
division of the patient TPM value by the healthy donor TPM value. Genes were 
considered to be upregulated in patients, if the TPM value of the patient gene 
was at least 10 and the fold change was at least 2-fold. If the fold change was 
0.35 or lower, and the TPM value of the healthy donor gene was at least 10, the 
gene was considered to be downregulated in patients. Enrichment analysis was 
performed using DAVID functional annotation clustering software (v6.8; 
https://david.ncifcrf.gov/). The samples were analyzed by the genomics core 
facility (University Marburg), and bioinformatic analysis was performed by Dr. 
Florian Finkernagel. 
Table 9: Enrichment analysis results. 
Term Genes P-Value Benjamini 
Natural killer cell-mediated cytotoxicity (hsa04650) 23 9*10-7 7,3*10-5 
Complement and coagulation cascades (hsa04610) 20 1,1*10-4 2,1*10-3 
Hippo signaling pathway (hsa04390) 24 6,5*10-2 2,7*10-1 
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2.2.2.4 Quantitative real-time PCR 
For the qRT-PCR, the Absolute qPCR SYBR Green Mix (Thermo Fisher 
Scientific) was used, according to the manufacturer’s protocol. The samples were 
measured in triplicates and analyzed on the Thermo Cycler Mx3005P from 
Stratagene.  
The following program was run: 
Initial activation step:  95 °C   15 min 
Denaturation:   95 °C   15s 
Annealing:    60 °C   20s      40 cycles 
Elongation:    72 °C   15s 
Denaturation:  95 °C   60s 
Melting curve:   72 °C-95 °C  30s 
Raw data were analyzed with the MxPro 4.01 software from Stratagene for the 
calculation of Ct values or with the Cy0 method. Genes that showed a Ct/Cy0 
value of 35 or higher were considered to be not expressed. In figures, this is 
indicated by a square. For the analysis, the Ct/Cy0 value of hRPL27 or hGAPDH 
of each sample was subtracted from the Ct/Cy0 value of the gene of interest. 
Afterward, the mean hRPL27 of all Ct/Cy0 values of the measurement was added 
to the calculated difference of the samples.  
The standard deviation was calculated as follows:  
Standard deviation 𝑆𝐷𝑇𝑜𝑡𝑎𝑙 = √(𝑆𝐷(ℎ𝑅𝑃𝐿27)
2 + 𝑆𝐷(𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡)
2 ) 
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2.2.3 Protein biochemical methods 
2.2.3.1 Western Blot 
Whole-cell lysates were made with RIPA lysis buffer together with protease 
inhibitors (1:1000) and phosphatase inhibitors (1:10). Protein concentration was 
determined by using the BCA protein assay kit (Thermo Fisher Scientific) 
according to the manufacture’s protocol. 5 µg protein was loaded onto an 8 % or 
12.5 % SDS polyacrylamide gel and separated with 1x SDS running buffer. Next, 
the samples were blotted on 0.2 µm nitrocellulose membranes (GE Healthcare) 
using 1x blotting buffer. The membrane was blocked with 5 % BSA in TBS-T for 
one hour at room temperature before it was incubated with primary antibody in 
5 % BSA in TBS-T overnight at 4 °C. After washing with TBS-T, the membrane 
was incubated with HRP-labeled secondary antibody in TBS-T. Following several 
rounds of TBS-T washing steps, the proteins were detected with Immobilon Forte 
Western HRP substrate solution (Millipore) using the chemiluminescence imager 
ChemiDoc (Bio-Rad).  
2.2.3.2 ELISA 
The IFNγ ELISA (ELISA MAXTM Standard Set Human IFN-γ) was obtained from 
Biolegend and conducted according to the manufacturer’s protocol. Supernatants 
were centrifuged at 300 g for 5 minutes and used either undiluted or diluted up to 
1:20 with assay diluent.  
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3 Results 
NK cells are a crucial part of the innate immune system and play a major role in 
tumor immune surveillance. However, healthy cells should not be attacked by NK 
cells. Since the NK cell response is very powerful, it needs to be tightly controlled 
by the balance between activating and inhibitory receptor signaling [219]. 
3.1 Human macrophages do not express NKG2D and 
macrophage killing by NK cells occurs NKG2D-independent 
One of the best-characterized activating receptors of NK cells is NKG2D, which 
binds to MICA/B and ULBP1-6 in humans. Those ligands are expressed on 
malignant or virus-infected cells but are absent on healthy cells [179].  
Of note, reflecting its importance NK cell function of many tumor patients is 
restricted, which is often due to tumor-associated immune escape mechanisms. 
One described mechanism is the shedding of membrane-bound NKG2D-Ls via 
metalloproteases, which leads to a downregulation of NKG2D and thus impairs 
NK cell and T cell function [80] [202] [222].  
High amounts of soluble MICA (sMICA) and soluble ULBP2 (sULBP2) were 
detectable in the ascites of ovarian cancer patients and negatively correlated with 
the RFS of the patients. Moreover, high amounts of sNKG2D-Ls also positively 
correlate with the amount of pro-tumorigenic CD163+CD206+ TAMs [221]. 
Surprisingly, NKG2D expression on patient-derived NK cells is not reduced [221] 
suggesting that the role of soluble NKG2D ligands within the ovarian cancer 
microenvironment is more complex than anticipated and does not exclusively 
function via NKG2D downregulation. 
It has been described that NKG2D is expressed on activated murine 
macrophages [59] indicating that NKG2D-NKG2D-L axis may also interfere with 
macrophage activity or polarization. Nevertheless, the expression of NKG2D on 
human macrophages is still under debate. Therefore, NKG2D expression was 
analyzed in freshly isolated ascites samples of ovarian cancer patients. In these 
samples, NKG2D was not detectable on the surface of TAMs (Fig. 1A). Moreover, 
NKG2D was undetectable on the surface of human healthy donor monocyte-
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derived macrophages (MDMs) (Fig. 1B), but it could be detected on NK cells and 
its expression was upregulated by stimulation with IL-2 and IL-15 (Fig. 1C). 
Furthermore, NKG2D was also not expressed in MDMs on mRNA level, while it 
was expressed in NK cells and T cells. Stimulation with LPS did not induce the 
expression of KLRK1 (NKG2D receptor) (Fig. 1D).  
In mice, Deng et al. nicely showed that NKG2D-L-expressing macrophages 
engage NKG2D on NK cells, and thereby induce NKG2D internalization and 
desensitization of NK cells. Of note, soluble NKG2D-Ls blocked these 
interactions, and restored NKG2D expression, thereby stimulating anti-tumor 
activity of NK cells and inducing tumor rejection [58]. The scenario in the ovarian 
cancer TME is obviously different since soluble NKG2D ligands in the ovarian 
TME are associated with a short survival time [221]. To test whether a NKG2D-
ligand and NKG2D-mediated crosstalk between macrophages and NK cells is at 
least possible, I investigated whether NKG2D-Ls are expressed and inducible 
with LPS on macrophages from healthy donors and TAMs. Therefore, monocytes 
of healthy donors were differentiated into macrophages for at least six days 
without the polarization through cytokines, before they were treated with LPS for 
the indicated time points. On mRNA level, MICA and MICB were detectable and 
the expression was further increased by LPS stimulation (Fig. 1E and F; see 
Table S1 and S2 for Ct values). Since the expression of ULBP2 was close to the 
detection limit, the variation between the donors was higher and no significant 
differences were seen after 48 hours and 72 hours of stimulation. However, the 
same tendency as for MICA and MICB could be seen (Fig. 1G; see Table S3 for 
Ct values). The expression of ULBP1 and ULBP3 could not be detected. 
However, MICA and MICB were not detected on the surface of healthy donor 
macrophages, while ULBP2 was weakly expressed (data not shown). In addition, 
MICA and MICB were also not expressed on the surface of TAMs (data not 
shown). Conversely, ULBP2 was clearly expressed on TAMs of two patients, 
while it was almost absent on TAMs of one patient (Fig. 1H). Thus, this data 
suggests that the NKG2D pathway might play a role in macrophage-NK cell 
crosstalk in the ovarian TME.  
 
Results  55 
 
 
  
A B 
C D 
H 
E F 
G 
Results  56 
 
Fig. 1: NKG2D receptor and ligand expression on immune cells.  
Flow cytometry analysis of NKG2D receptor expression on TAMs (A), healthy donor MDMs (B) 
and healthy donor NK cells (positive control) (C). NK cells were stimulated with 200 U/ml IL-2 and 
10 ng/ml IL-15 overnight to induce enhanced NKG2D expression (red histogram). Representative 
data of three independent biological replicates are displayed. qRT-PCR analysis of NKG2D 
receptor expression was performed for NK cells, T cells and MDMs (D). MDMs were differentiated 
for 6 days and then stimulated with 100 ng/ml LPS for 24 hours before harvesting. Representative 
data of two independent biological replicates are displayed. Bar graphs represent means of 
triplicates ± technical SD. MDMs were stimulated with 100 ng/ml LPS for 24, 48 or 72 hours. qRT-
PCR analysis of MICA (E), MICB (F) and ULBP2 (G) of MDMs was performed. Each color denotes 
a biological replicate (n = 7) and the median values are indicated by horizontal bars. For ULBP1 
and ULBP3, no Ct values were measured for any condition. Statistical significances were 
calculated using paired t-tests. (H) Flow cytometry analysis of ULBP2 expression on the surface 
of TAMs was performed. Data shown in Figure 1A and 1C was previously published in Vyas et 
al., 2017 [221]. 
ns, not significant (p ≥ 0.05), *p < 0.05, **p < 0.01, ***p < 0.001; MDMs, monocyte-derived macrophages; 
TAMs, tumor-associated macrophages; SD, standard deviation; LPS, lipopolysaccharide 
Next, I investigated, whether the ascites of ovarian cancer patients influences the 
expression of NKG2D-Ls on healthy donor macrophages on mRNA level and 
whether the amount of sNKG2D-Ls present in the ascites has an impact on the 
expression. Monocytes were differentiated into macrophages in the presence of 
ascites with high or low amounts of sNKG2D-Ls. In fact, the presence of ascites 
led to a reduced expression of MICA and MICB seen as a tendency. However, 
no differences were observed between ascites with high or low amounts of 
sNKG2D-Ls (Fig. 2). 
B A 
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Fig. 2: Influence of ascites on the NKG2D-L expression of MDMs. 
qRT-PCR analysis of MICA (A) and MICB (B) of MDMs. MDMs were differentiated for 6 days 
either in R5 medium or in 100 % ascites. The ascites samples were divided into two groups - one 
that contained high amounts of sNKG2D-Ls (asc 84, asc 90 and asc 58) and one that contained 
low amounts of sNKG2D-Ls (asc 80 and asc 82). Each color denotes a biological replicate (n = 3) 
and the median values are indicated by horizontal bars. 
MDMs, monocyte-derived macrophages; asc, ascites; sNKG2D-Ls, soluble NKG2D ligands 
Having seen that LPS induced upregulation of MICA and MICB on the 
transcriptional level (Fig. 1E and F), I analyzed, if LPS-treated macrophages are 
lysed more efficiently by NK cells in comparison to untreated macrophages owing 
to NKG2D signaling. Due to the LPS treatment, the macrophages showed higher 
basal viability, but they were not lysed more efficiently by NK cells. Furthermore, 
blocking of the NKG2D signaling did not result in reduced killing (Fig. 3), 
demonstrating that NK cell-mediated killing of macrophages is NKG2D-
independent.  
Fig. 3: Killing of MDMs by NK cells.  
Cytotoxic potential of activated NK cells against LPS-stimulated MDMs was determined in a 
FACS-based killing assay. MDMs were differentiated for 6 days, before half of the cells were 
further stimulated with 100 ng/ml LPS for 24 hours. NK cells were activated overnight with 
200 U/ml IL-2 and 10 ng/ml IL-15 and then incubated with untreated or LPS-treated MDMs as 
target cells at the effector to target cell (E:T) ratios 5:1, 10:1 and 20:1. Additionally, at the E:T 
ratio 20:1, NK cells were pre-incubated with 10 µg/ml α-NKG2D blocking antibody or matching 
isotype control before the co-incubation. Each color denotes a biological replicate (n = 2-4) and 
the median values are indicated by horizontal bars. 
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MDMs, monocyte-derived macrophages; LPS, lipopolysaccharide; E:T, effector to target cell ratio; w/o, 
without; NK, NK cell; 7-AAD, 7-aminoactinomycin D 
Taken together, the NKG2D receptor is not expressed on human healthy donor 
and ovarian cancer-associated macrophages, but the NKG2D-Ls MICA, MICB 
and ULBP2 are detectable on mRNA level and can be further induced by 
treatment with LPS. Expression of ULBP2 but not MICA/B was detectable on the 
protein level by flow cytometry. However, LPS-treated macrophages are not killed 
more efficiently by NK cells than untreated macrophages and the killing is 
NKG2D-independent. The expression of NKG2D-ligands of macrophages which 
are differentiated from monocytes in the presence of ascites was not affected or 
slightly reduced. 
3.2 Membrane-bound NKG2D-Ls (mNKG2D-Ls) and soluble 
NKG2D-Ls (sNKG2D-Ls) induce different target genes 
As described in section 3.1, the ascites of ovarian cancer patients contains high 
amounts of sMICA and sULBP2, but NKG2D is not downregulated on the surface 
of ovarian cancer patient-derived NK cells [221]. Therefore, the question arose, 
whether sNKG2D-Ls only passively block the receptor activation or whether the 
sNKG2D-Ls are able to induce signaling and gene expression via NKG2D 
receptor.  
To address this question, a system in which solely the NKG2D signal could be 
monitored without any signal from other receptors was needed. Hence, the 
Drosophila cell line Schneider S2 was used, which does not express any known 
ligands binding to NK cell receptors, due to their evolutionary distinction [29]. An 
S2 cell line was generated, which stably expressed ULBP2 on its surface 
(Fig. 4A) and which bound to the recombinant NKG2D receptor (Fig. 4B), 
confirming proper folding and functionality of the ligand.  
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Fig. 4: Generation of ULBP2-positive S2 cells. 
(A) Flow cytometry analysis of ULBP2 expression on S2 WT cells and stably transfected S2 
ULBP2 cells. Representative data of seven independent replicates are shown. (B) Flow cytometry 
analysis of bound recombinant NKG2D receptor on S2 WT cells and stably transfected S2 ULBP2 
cells was performed. Representative data of two independent replicates are shown. (C) 
Immunoblot analysis of pERK 1/2 was performed. IL-2 and IL-15-primed NK cells were incubated 
with S2 WT and S2 ULBP2 cells at the E:T ratio of 1:1 for 15 min at 37 °C before they were lysed. 
Representative data of four independent biological replicates are shown. Note, phosphorylation 
of ERK 1/2 after co-incubation with S2 ULBP2 cells was only visible in four out of eight donors. 
(D) IL-2 and IL-15-primed NK cells were incubated with S2 WT and S2 ULBP2 cells at the E:T 
ratio of 1:1 for 48 hours at 37 °C before the supernatant was collected, and the IFNγ level was 
measured by ELISA. In addition, S2 cells were incubated with a polyclonal α-S2 antibody for 30 
min, before they were co-incubated for 48 hours with NK cells in order to stimulate the NK cells 
A C 
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via CD16 as a positive control. Representative data of three to five independent biological 
replicates. (E) Cytotoxic potential of activated NK cells against S2 WT and S2 ULBP2 cells was 
determined in a FACS-based degranulation assay. NK cells were activated overnight with 200 
U/ml IL-2 and 10 ng/ml IL-15 and then incubated with S2 cells as target cells at the E:T ratio 1:1. 
In parallel, NK cells were pre-incubated with 10 µg/ml α-NKG2D blocking antibody or matching 
isotype control before the co-incubation. Each color denotes a biological replicate (n = 3-5) and 
the median values are indicated by horizontal bars. Statistical significances were calculated using 
paired t-tests (pairing based on replicate groups). 
*p < 0.05; WT, wild type; E:T, effector to target cell; min, minutes; crossl., crosslinking 
Next, it was tested if ULBP2-expressing S2 cells can activate primary human NK 
cells. Indeed, the cultivation of NK cells with S2-ULBP2 cells led to 
phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) (Fig. 4C). 
However, it must be noted, that this was highly donor-dependent and could not 
be seen in all donors tested. Furthermore, the cultivation of NK cells with S2-
ULBP2 cells, but not with S2 WT cells, led to the secretion of IFNγ. The level was 
even higher when the NK cells were stimulated in parallel via the CD16 receptor, 
showing a synergistic effect (Fig. 4D). This is in line with the function of NKG2D 
as a co-stimulating receptor [30]. Finally, the cultivation of NK cells with S2-
ULBP2 cells led to the degranulation of NK cells, shown by the increased 
presence of CD107a on the surface of NK cells. The degranulation was not 
observed, when the NKG2D receptor was blocked shortly before the assay was 
conducted, showing, that the degranulation of NK cells was NKG2D-dependent 
(Fig. 4E). 
Since S2-ULBP2 cells can activate NK cells in a NKG2D-dependent manner, 
these cells were used as a model for NKG2D-engagement via membrane-bound 
NKG2D-L (mULBP2). To analyze the activity of soluble NKG2D-Ls, a 
recombinant protein was used. This protein (immunoligand) is a fusion protein of 
ULBP2 and an antibody fragment (BB4). It was previously shown that coating of 
target cells with an immunoligand enhanced the activation of NK cells by NKG2D 
signaling [172]. However, if the ligand is used without target cells, it should mimic 
the engagement of a sNKG2D-L. In order to prime NK cells and upregulate 
NKG2D, the cells were stimulated with IL-2 and IL-15 before the cells were 
incubated with S2 WT, S2 ULBP2 cells (mULBP2) or sULBP2-BB4 (sULBP2). To 
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identify target genes of NKG2D-stimulation through membrane-bound versus 
soluble ULBP2, RNA-seq was performed. NK cells stimulated with IL-2 and IL-15 
alone were used as a control. Due to a short co-cultivation time of NK cells and 
S2 cells, the cells could not be separated before the RNA isolation. However, 
since S2 cells originated from a different species, the Drosophila specific reads 
within the RNA-seq could be subtracted from the human alignment. Through the 
RNA-seq, ten mULBP2-specific target genes and twelve sULBP2-specific target 
genes could be identified (Table 10; see Table S4 and S6 for TPM values, and 
S5 and S7 for fold change values). Looking at the mNKG2D-L-specific target 
genes, CCR6 was the only one being downregulated, while all other genes were 
induced, amongst them classical activation genes of NKG2D signaling, like CD69 
and TNF. As expected, human ULBP2 could be detected due to the presence of 
S2 ULBP2 cells, serving as an internal control (Table 10; see Table S4 for TPM 
values, and S5 for fold change values). Genes that were induced after sNKG2D-L 
engagement were, for example, ACOD1, CEMIP, CLEC4E, and PLA2G7 
(Table 10; see Table S6 for TPM values, and S7 for fold change values). 
Table 10: Identification of membrane-bound ULBP2 (mULBP2) and soluble ULBP2 
(sULBP2) target genes via RNA-seq and expression status in comparison to the 
corresponding control. 
NK cells were primed with IL-2 and IL-15 for 16 hours and then incubated with S2 WT (negative 
control) or S2 ULBP2 cells (membrane-bound ULBP2) at the E:T ratio of 1:1 for 2 hours at 37 °C 
before they were lysed. In parallel, NK cells were stimulated with IL-2, IL-15 and 20 µg/ml 
sULBP2-BB4 (sULBP2) for 18 hours at 37 °C before the cells were lysed, RNA was isolated, and 
cDNA libraries were sequenced on an Illumina HiSeq 1500. As a control for the sULBP2, NK cells 
were only stimulated with IL-2 and IL-15 for 18 hours at 37 °C. In this experiment, a total of three 
independent biological replicates was used. Raw reads were aligned to the human and Drosophila 
genomes (retrieved from Ensembl 97) using STAR 2.6.1d. Reads aligning to the Drosophila 
genome were subtracted from the human alignment. Read counts were quantified in exonic 
regions of protein-coding transcripts and normalized to TPM. Differential gene expression was 
assessed via edgeR (version 3.24.3) at a threshold of FDR ≤ 0.05 and |log2FC| ≥ 1. Arrows and 
equation signs show whether the genes were upregulated, downregulated or whether the 
expression status was unaltered in at least two out of three donors, after stimulation with mULBP2 
or sULBP2.  
Results  62 
 
The RNA-seq was conducted by the IKMB (University Kiel), and the data were analyzed by Dr. Florian 
Finkernagel.  
Next, the identified target genes were validated via qRT-PCR. ACOD1 (Fig. 5A), 
CLEC4E (Fig. 5B) and PLA2G7 (Fig. 5C) were not expressed in freshly isolated 
NK cells. Priming with IL-2 and IL-15 led to weak basal expression of the genes, 
but stimulation with sULBP2-BB4 led to increased gene expression. To exclude 
any contribution of the BB4 part of the ULBP2 fusion protein, soluble BB4 was 
used as a control. sBB4 did not induce expression of the identified target genes. 
Furthermore, commercially available, recombinant sULBP2-His also induced the 
expression of ACOD1, CLEC4E, and PLA2G7, even though the upregulation was 
not as strong as after engagement of sULBP2-BB4 (Fig. 5).  
Summing up, I could provide first evidence that sNKG2D-Ls induce target gene 
expression. Novel target genes of NKG2D by engagement of mNKG2D-Ls (see 
above) and by engagement of sNKG2D-Ls (ACOD1, CLEC4E, and PLA2G7) 
were identified.  
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Fig. 5: qRT-PCR validation of soluble ULBP2-induced target genes. 
Validation of RNA-seq hits, which were significantly upregulated by sULBP2-BB4, via qRT-PCR 
analysis of (A) ACOD1, (B) CLEC4E and (C) PLA2G7 was conducted. The graphs show the Cy0 
values of the indicated genes that were normalized to RPL27. Each color denotes an independent 
biological replicate (n = 7) and the median values are indicated by horizontal bars. Squares 
indicate no measured Cy0 value. Statistical significances were calculated using paired t-tests for 
samples by which a Cy0 value was measured. 
*p < 0.05, **p < 0.01, ***p < 0.001; s, soluble; d0, day 0 
3.3 Ovarian cancer patient-derived NK cells show a tumor-
associated phenotype 
NK cells play an important role in the recognition and elimination of malignant 
cells [115]. Therefore, tumor cells try to avoid NK cell recognition by various 
escape mechanisms, such as shedding of activating ligands via metalloproteases 
[80] [222]. However, in ovarian cancer, NK cell impairment does not follow 
conventional inhibition strategies. Therefore, a global characterization of tumor-
associated NK cells is needed to understand their role in ovarian cancer and thus, 
to identify novel potential target sites.  
At first, surface expression of various NK cell activating receptors and inhibitory 
receptors, as well as the expression of exhaustion markers was investigated in 
one of the largest cohorts so far. Therefore, peripheral blood mononuclear cells 
(PBMCs) and ascites-derived peritoneal cells (PCs) of ovarian cancer patients 
were analyzed using flow cytometry. PBMCs from healthy blood donors were 
used as a control.  
The number of NK cells within the ascites was slightly increased, even though 
this did not reach statistical significance (Fig. 6A). However, the MFI of CD56 was 
increased, hinting at an increased number of CD56bright CD16low NK cells, which 
produce higher amounts of cytokines but are less cytotoxic than CD56dim CD16high 
NK cells [51] (Fig. 6B). This was in line with a reduced expression of CD16 
(Fig. 6C and D). 
Since the NKG2 family consists of activating and inhibitory receptors, it was 
important to determine the status of those in ovarian cancer, because the balance 
Results  65 
 
between those receptors determines whether the NK cells are activated or not 
[115]. While NKG2A (an inhibitory receptor) and NKG2D (an activating receptor), 
were upregulated, NKG2C, which is also an activating receptor, was 
downregulated on ascites-derived NK cells (Fig. 7) [22]. 
Fig. 6: Characterization of NK cells of ovarian cancer patients.  
PBLs of healthy donors, PBMCs of the blood and ascites-derived PCs of ovarian cancer patients 
were analyzed using flow cytometry. Scatter plots show the percent NK cells of lymphocytes (A), 
MFI of CD56 (B), percent CD16-positive NK cells (C) and MFI of CD16 (D). Each symbol denotes 
A B 
C D 
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a biological replicate (n = 19-68) and the median values are indicated by horizontal bars. 
Statistical significances were calculated using unpaired t-tests without Welch’s corrections. 
ns, not significant (p ≥ 0.05), *p < 0.05, **p < 0.01, ****p ≤ 0.0001; PBL, peripheral blood lymphocytes; 
PBMCs, peripheral blood mononuclear cells; PCs, peritoneal cells; HD, healthy donor; MFI, mean 
fluorescence intensity  
Fig. 7: Analysis of NKG2 family member expression on ovarian cancer patient-derived NK 
cells. 
PBLs of healthy donors, PBMCs of the blood and ascites-derived PCs of ovarian cancer patients 
were analyzed using flow cytometry. Scatter plots show the percentage of NKG2A, NKG2C, 
NKG2D, and CD94 positive NK cells. Each symbol denotes a biological replicate (n = 15-68) and 
the median values are indicated by horizontal bars. Statistical significances were calculated using 
unpaired t-tests without Welch’s corrections. 
*p < 0.05, **p < 0.01, ****p ≤ 0.0001; PBL, peripheral blood lymphocytes; PBMCs, peripheral blood 
mononuclear cells; PCs, peritoneal cells; HD, healthy donor  
Another prominent family providing activating receptors are the NCRs. To this 
family belong the receptors NKp30, NKp44 and NKp46 [166] [199] [218], which 
are all downregulated on patient-derived NK cells (Fig. 8). Furthermore, yet 
another prominent activating receptor, DNAM-1, was strongly downregulated on 
patient-derived NK cells (Fig. 8). 
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Fig. 8: Analysis of NCR family member and DNAM-1 expression on ovarian cancer patient-
derived NK cells. 
PBLs of healthy donors, PBMCs of the blood and ascites-derived PCs of ovarian cancer patients 
were analyzed using flow cytometry. Scatter plots show the percentage of NKp30, NKp44, NKp46, 
and DNAM-1 positive NK cells. Each symbol denotes a biological replicate (n = 12-68) and the 
median values are indicated by horizontal bars. Statistical significances were calculated using 
unpaired t-tests without Welch’s corrections. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001; PBL, peripheral blood lymphocytes; PBMCs, peripheral 
blood mononuclear cells; PCs, peritoneal cells; HD, healthy donor; NCR, natural cytotoxicity receptors 
KIRs consist of inhibitory receptors and a few activating receptors. CD158a 
(KIR2DL1), CD158b (KIR2DL3) and CD158e (KIR3DL1) all belong to the 
inhibitory receptors [74]. The CD158a expression was not altered in comparison 
to healthy donor NK cells, but CD158b and especially CD158e were 
downregulated on ascites-derived NK cells (Fig. 9). 
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Fig. 9: Analysis of KIR family member expression on ovarian cancer patient-derived NK 
cells.  
PBLs of healthy donors, PBMCs of the blood and ascites-derived PCs of ovarian cancer patients 
were analyzed using flow cytometry. Scatter plots show the percentage of CD158a, CD158b, and 
CD158e positive NK cells. Each symbol denotes a biological replicate (n = 19-68) and the median 
values are indicated by horizontal bars. Statistical significances were calculated using unpaired 
t-tests without Welch’s corrections. 
***p < 0.001, ****p ≤ 0.0001; PBL, peripheral blood lymphocytes; PBMCs, peripheral blood mononuclear 
cells; PCs, peritoneal cells; HD, healthy donor; KIR, killer-cell immunoglobulin-like receptors 
Finally, the activation and exhaustion status of the NK cells was analyzed. CD69, 
an early activation marker, was strongly expressed on ascites-derived NK cells. 
Moreover, expression of the co-inhibitory receptors PD-1 and TIM-3, also known 
as immune checkpoint targets, was detected on NK cells of some patients. 
Surprisingly, the expression of another co-inhibitory receptor, TIGIT, was 
downregulated on the ascites-derived NK cells (Fig. 10). 
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Fig. 10: Analysis of exhaustion marker and the early activation marker CD69 expression 
on ovarian cancer patient-derived NK cells. 
PBLs of healthy donors, PBMCs of the blood and ascites-derived PCs of ovarian cancer patients 
were analyzed using flow cytometry. Scatter plots show the percentage of PD-1, CD69, TIGIT, 
and TIM-3 positive NK cells. Each symbol denotes a biological replicate (n = 12-67) and the 
median values are indicated by horizontal bars. Statistical significances were calculated using 
unpaired t-tests without Welch’s corrections. 
ns, not significant (p ≥ 0.05), *p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001; PBL, peripheral blood 
lymphocytes; PBMCs, peripheral blood mononuclear cells; PCs, peritoneal cells; HD, healthy donor 
In conclusion, patient-derived NK cells show a mixed tumor-associated 
phenotype, in which most of the activating receptors are downregulated and the 
expression status of the inhibitory receptors was mixed (Table 11). Furthermore, 
they showed a high expression of the early activation marker CD69 and NKG2D, 
which are known as cytotoxicity receptors. Besides, the expression of exhaustion 
markers (PD-1 and TIM-3) was detectable (see Table 11 as a summary). 
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Table 11: Summary surface marker expression on patient-derived NK cells in comparison 
to healthy donor NK cells.  
 
3.4 Reduced cytotoxic potential of ovarian cancer patient-
derived NK cells can be partially restored by IL-2 and IL-15  
Since the expression of various activating receptors was downregulated whereas 
expression of CD69 and NKG2D was enhanced, I investigated the cytotoxic 
potential of patient-derived NK cells. Therefore, freshly isolated ascites-derived 
NK cells were cultivated with K562 target cells either in standard medium or 
medium supplemented with 25 % ascites. Both showed a strongly reduced 
degranulation against target cells in comparison to healthy donor NK cells (18.5 % 
vs. 39 %). However, this reduced cytotoxic potential is restored, when the NK 
cells were stimulated with IL-2 and IL-15. The killing activity could be further 
increased, when NK cells were cultivated without any addition of ascites fluid 
(Fig. 11). Of note, basal degranulation of freshly isolated NK cells and resting NK 
cells without target cells was around 5 %, while basal degranulation of activated 
NK cells without target cells was slightly increased up to around 11 % (data not 
shown). 
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Fig. 11: Cytotoxic activity of healthy donor NK cells and ovarian cancer patient ascites-
derived NK cells against K562. 
Cytotoxic potential of freshly isolated NK cells, resting NK cells (rNKs; 10 U/ml IL-2 overnight) and 
activated NK cells (aNKs; 200 U/ml IL-2 and 10 ng/ml IL-15 overnight) against K562 as target a 
target cell line was determined in a FACS-based degranulation assay. NK cells and K562 were 
co-cultivated at an E:T ratio of 5:1 for six hours, before degranulation was analyzed using flow 
cytometry. Healthy donor NK cells (HD) were cultivated in medium. Ascites-derived NK cells (OC) 
were cultivated with normal medium and normal medium supplemented with 25 % ascites. For 
freshly isolated NK cells, the assay itself was conducted in medium or medium supplemented 
with 25 % ascites. Each symbol denotes a biological replicate (HD: n = 5, OC: n = 10-13) and the 
median values are indicated by horizontal bars. Statistical significances were calculated using 
unpaired t-tests. 
ns, not significant (p ≥ 0.05), *p < 0.05, **p < 0.01, ***p < 0.001; HD, healthy donor; OC, ovarian cancer 
patient; rNK, resting NK cells; aNKs, activated NK cells; asc, ascites; E:T, effector : target 
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Next, I analyzed which activating receptors play a major role in the recognition 
and elimination of ovarian cancer cells. Therefore, the ovarian cancer cell line 
OVCAR-4 was used as target cells and different activating receptors were 
blocked. Resting peripheral blood lymphocytes (rPBLs) showed significantly 
lower degranulation and less killing of OVCAR-4, when the activating receptors 
DNAM-1 and NKG2D were blocked (Fig. 12A and B). The degranulation of the 
PBLs and killing of the target cells was higher when they were primed with IL-2 
and IL-15 overnight (aPBLs), as expected. Again this was dependent on DNAM-1 
and NKG2D, too (Fig. 12C and D). Furthermore, blocking of CD16 led to a 
reduced killing of the target cells, but interestingly to a higher degranulation 
(Fig. 12C and D). However, the killing of the target cells and the degranulation of 
the NK cells was not completely abolished by blocking a single activating 
receptor, hinting to a dependency on multiple activating receptors. Nonetheless, 
when the healthy PBLs were cultivated in ascites, they were no longer able to 
degranulate and kill the target cells (Fig. 12E and F).  
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Fig. 12: The impact of ascites on healthy donor NK cells and the role of different NK cell 
activation receptors for the recognition and lysis of OVCAR-4. 
Cytotoxic potential of resting (untreated) or activated healthy donor PBLs (200 U/ml IL-2 and 
10 ng/ml IL-15 overnight) against OVCAR-4 was determined in a FACS-based assay. PBLs were 
pre-treated with 10 µg/ml blocking antibodies against NKp30, DNAM-1, NKG2D, and CD16, 
respectively or matching isotype control for 30 minutes before the assay was performed. (A) 
rPBLs and OVCAR-4 were co-cultivated at an E:T ratio of 100:1 for 6 hours, before degranulation 
was analyzed using flow cytometry. For the analysis, NKp46-positive NK cells were gated. Each 
color denotes a biological replicate (n = 11), and the median values are indicated by horizontal 
bars. (B) Depicted is a FACS-based killing assay of healthy donor rPBLs against OVCAR-4 at an 
E:T ratio of 100:1. Each color denotes a biological replicate (n = 10) and the median values are 
indicated by horizontal bars. (C) aPBLs and OVCAR-4 were co-cultivated at an E:T ratio of 100:1 
for 6 hours, before degranulation was analyzed using flow cytometry. For the analysis, it was 
gated on NKp46-positive NK cells. Each color denotes a biological replicate (n = 8) and the 
median values are indicated by horizontal bars. (D) FACS-based killing assay of healthy donor 
aPBLs against OVCAR-4 at an E:T ratio of 100:1 were performed. Each color denotes a biological 
replicate (n = 8) and the median values are indicated by horizontal bars. Statistical significances 
were calculated using paired t-tests. (E) PBLs were incubated for 48 hours in medium or 100 % 
ascites of an ascites pool of 5 patients, together with 10 U/ml IL-2. Then, a FACS-based 
degranulation assay was performed at an E:T ratio of 100:1. For the analysis, it was gated on 
NKp46-positive NK cells. Each color denotes a biological replicate (n = 3) and the median values 
are indicated by horizontal bars. (F) PBLs were incubated for 48 hours in medium or 100 % ascites 
of an ascites pool of 5 patients, together with 10 U/ml IL-2. Then, a FACS-based killing assay was 
performed at an E:T ratio of 100:1. Each color denotes a biological replicate (n = 3) and the 
median values are indicated by horizontal bars. 
ns, not significant (p ≥ 0.05), *p < 0.05, **p < 0.01, ***p < 0.001; HD, healthy donor; rPBL, resting peripheral 
blood lymphocytes; aPBL, activated peripheral blood lymphocytes; E:T, effector : target  
Taken together, ascites-derived NK cells show a diminished cytotoxic potential, 
which can be restored when the cells are activated by IL-2 and IL-15 and are no 
longer influenced by the ascites. Hence, the effect of ascites is reversible. 
Conversely, healthy donors NK cells are immediately influenced by the presence 
of ascites and are no longer able to kill target cells. Furthermore, the killing of 
ovarian cancer cells is predominantly dependent on DNAM-1 and NKG2D 
signaling.  
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3.5 TGFβ in ovarian cancer ascites mediates DNAM-1 
downregulation and impairs NK cell cytotoxicity 
In section 3.4 it was observed that the killing of ovarian cancer cells depends on 
the signaling of NKG2D and DNAM-1. Nevertheless, it was also observed that 
NKG2D was not downregulated on ascites-derived NK cells, but the DNAM-1 
expression was strongly decreased (Fig. 7 and 8). Therefore, I wanted to 
investigate which factor present in the ascites is responsible for the 
downregulation of DNAM-1. It has already been described that TGFβ can reduce 
the expression of DNAM-1 [83] and that TGFβ is present in the ascites of ovarian 
cancer patients. In particular, TGFβ1 was associated with a reduced RFS [181].  
Hence, the effect of ascites on the expression of DNAM-1 with or without TGFβ 
inhibition was analyzed. Cultivation of healthy donor NK cells in ascites led to a 
downregulation of DNAM-1 on mRNA and on protein level, which could be 
abrogated by both a TGFβ receptor kinase inhibitor or a TGFβ blocking antibody 
(Fig. 13). Moreover, recombinant TGFβ1 downregulates DNAM-1 on mRNA level 
and on protein level and this downregulation could be partially blocked by the 
presence of a TGFβ receptor kinase inhibitor (SB-431542) or a TGFβ blocking 
antibody (Fig. 13). However, no detectable differences were observed on the 
magnitude of CD226 downregulation, when ascites of patients with high or low 
amounts of TGFβ1 were used (data not shown). Nevertheless, it must be noted 
that only a small sample size was analyzed. Moreover, it was observed that the 
effect of TGFβ1 and ascites had a greater impact on the expression of the CD226 
mRNA than on the expression of DNAM-1 on the surface. Of note, the cultivation 
of primary NK cells itself led to diminished expression of CD226 on mRNA level, 
but this was not as strong as in the presence of TGFβ and not affected by TGFβ 
inhibition (data not shown).  
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Fig. 13: DNAM-1 expression of healthy donor NK cells is decreased by TGFβ that is found 
in ovarian cancer ascites. 
(A) The Scatter plot displays the CD226 expression in healthy donor NK cells that were cultivated 
in medium + 1 ng/ml TGFβ1 or 100 % ascites. Furthermore, the effect of TGFβ was blocked by 
using a TGFβ blocking antibody (5 µg/ml) or a TGFβ receptor kinase inhibitor (SB-431542; 
10 µM). Each symbol denotes a biological replicate (n = 3-12) and the median values are 
indicated by horizontal bars. Statistical significances were calculated using paired t-tests. (B) 
DNAM-1 expression on the surface of healthy donor NK cells was analyzed using flow cytometry. 
NK cells were cultivated and treated as in (A). Each symbol denotes a biological replicate 
(n = 5-15) and the median values are indicated by horizontal bars. Statistical significances were 
calculated using paired t-tests. Of note, viability of NK cells was monitored and cultivation of 
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primary human NK cells led to decreased viability. However, the lower viability had only a minor 
impact on the expression of DNAM-1. Plasma was not used as a control for the ascites since pure 
plasma is much higher concentrated than within the blood and viability of the cells cultured in pure 
plasma is strongly decreased. Therefore, it does not mimic the physiological situation. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001; HD, healthy donor; asc, ascites; AB, antibody; Inh., 
inhibitor; MFI, mean fluorescence intensity; d0, day 0 
Next, it was investigated, whether abrogation of the TGFβ signaling could restore 
the degranulation capacity of patient-derived NK cells. Therefore, the target cell 
line K562 was used, as their killing is also dependent on DNAM-1 (Fig. 14A). 
Indeed, blockage of the TGFβ signaling led to a higher degranulation of resting 
ascites-derived NK cells (Fig. 14B). Here, the degranulation of resting NK cells 
after blockage of the TGFβ signaling was as high as the degranulation of 
cytokine-primed, activated NK cells after blockage of the TGFβ signaling (data 
not shown). This showed that the TGFβ present in the ascites of the patients is 
responsible for the lower cytotoxic potential of the NK cells. The blockage of the 
TGFβ signaling fully restored the cytotoxic potential of the NK cells with no 
requirement for activation by cytokines. Freshly isolated NK cells did not respond 
to the blocking of the TGFβ signaling probably due to the short assay duration. 
Moreover, the TGFβ signaling blockage also led to enhanced expression of 
DNAM-1 on the surface of the patient-derived NK cells (Fig. 14C).  
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Fig. 14: Impact of DNAM-1 and TGFβ blockage on the cytotoxicity of NK cells against K562 
cells.  
(A) FACS-based degranulation assay of healthy donor NK cells using K562 as a target cell line 
at different E:T ratios with or without DNAM-1 blockage was performed. Dots represent the means 
of four independent biological replicates ± SD. (B) Depicted is a degranulation assay of ovarian 
cancer patient NK cells. The ascites-derived NK cells were cultivated with normal medium or 
normal medium supplemented with 25 % ascites and stimulated with 10 U/ml IL-2 overnight 
(rNKs), before the killing of K562 was determined in a FACS-based degranulation assay. In 
parallel, TGFβ signaling was blocked before the cells were seeded by using a TGFβ blocking 
antibody (5 µg/ml) or a TGFβ receptor kinase inhibitor (SB-431542; 10 µM). The antibody and the 
inhibitor were present during the whole cultivation time. NK cells and K562 were co-cultivated at 
an E:T ratio of 5:1 for 6 h, before degranulation was analyzed using flow cytometry. In addition, 
NK cells were pre-treated with 10 µg/ml DNAM-1 blocking antibody or matching isotype control 
for 30 minutes before the degranulation assay was performed. Each symbol denotes a biological 
replicate (n = 1-4) and the median values are indicated by horizontal bars. (C) Shown is the 
DNAM-1 expression of ascites-derived NK cells after cultivation overnight with 10 U/ml IL-2 and 
TGFβ blocking antibody (5 µg/ml) or a TGFβ receptor kinase inhibitor (SB-431542; 10 µM). 
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Representative data of two biological independent replicates (for the blocking antibody just one 
patient) is shown. 
HD, healthy donor; OC, ovarian cancer patient; rNK, resting NK cells; asc, ascites; E:T, effector : target; AB, 
antibody; Inh., inhibitor; MFI, mean fluorescence intensity; d0, day 0 
Summing up, TGFβ present in the ascites of ovarian cancer patients is 
responsible for the downregulation of DNAM-1 on mRNA and protein level. 
Hence, a blockage of the TGFβ signaling leads to an increased expression of 
DNAM-1 on patient-derived NK cells and restored cytotoxic potential of the NK 
cells.  
3.6 Tumor-associated NK cells show dysregulation of the kegg 
pathways natural killer cell-mediated cytotoxicity, the Hippo 
pathway, and several complement factors 
I have shown that the balance between activating and inhibitory receptors of 
patient-derived NK cells is altered and that the NK cells show a reduced cytotoxic 
potential. However, the molecular changes were not analyzed yet. Thus, RNA-
seq of NK cells derived from six patients was performed and the results were 
compared to RNA-seq results of healthy donor NK cells. Here, 1811 genes were 
upregulated in patient-derived NK cells, while 1224 genes were downregulated 
in comparison to healthy donor NK cells. Enrichment analysis using DAVID 
functional annotation clustering software identified several pathways being 
dysregulated in patient-derived NK cells. Among these was the kegg pathway 
natural killer cell-mediated cytotoxicity (hsa04650) from which 23 genes showed 
an altered gene expression (Fig. 15A). To those genes belonged ZAP70, 
FCGR3A, VAV1, and VAV3, which were all downregulated in patient-derived NK 
cells (Fig. 15B and C). Next, the RNA-seq results were validated using qRT-PCR 
and it could be confirmed that the expression of FCGR3A, VAV1, CD226, and 
HLA-E was diminished in the ascites-derived NK cells (Fig. 15D). 
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Fig. 15: Comparison of healthy donor NK cells and ascites -derived ovarian cancer patient 
NK cells by RNA-seq defines a dysregulation of natural killer cell-mediated cytotoxicity 
genes. 
Identification of differentially expressed genes in healthy donor NK cells (HD) versus ascites-
derived patient NK cells (OC) based on RNA-seq data. Raw reads were aligned to the human 
genome (retrieved from Ensembl 92) using STAR 2.4.1a. Read counts were quantified in exonic 
regions of protein-coding transcripts and normalized to TPM. (A) The Venn diagram shows the 
overlap of genes that were downregulated in patient-derived NK cells in comparison to healthy 
donor NK cells, and genes belonging to the kegg pathway natural killer cell-mediated cytotoxicity. 
(B) The heatmap shows the expression of cytotoxicity genes (depicted is the TPM value) that 
were significantly differentially expressed between healthy donor NK cells and ovarian cancer 
patient NK cells. (C) Scatter plot showing TPM values of ZAP70, FCGR3A, VAV1, and VAV3 
based on RNA-seq results. Each symbol denotes a replicate (n = 4-6) and the median values are 
B 
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indicated by horizontal bars. (D) The validation of RNA-seq hits via qRT-PCR analysis of 
significantly differentially expressed genes is depicted. The graph shows the Cy0 values of the 
indicated genes that were normalized to GAPDH. Each symbol denotes an independent biological 
replicate (n = 7) and the median values are indicated by horizontal bars. Statistical significances 
were calculated using unpaired t-tests without Welch’s corrections. 
**p < 0.01, ****p ≤ 0.0001; HD, healthy donor; OC, ovarian cancer patient; TPM, transcripts per million reads  
The RNA-seq was conducted by the genomics core facility (University Marburg), and the data was analyzed 
by Dr. Florian Finkernagel. 
Fig. 16: Comparison of healthy donor NK cells and ascites-derived ovarian cancer patient 
NK cells by RNA-seq identifies upregulation of complement factors. 
Identification of differentially expressed genes of the complement system in healthy donor NK 
cells (HD) versus ascites-derived patient NK cells (OC) based on RNA-seq data. Raw reads were 
aligned to the human genome (retrieved from Ensembl 92) using STAR 2.4.1a. Read counts were 
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quantified in exonic regions of protein-coding transcripts and normalized to TPM. Scatter plot 
showing TPM values of C3, CFB, CFI, and C2 based on RNA-seq results (A). Each symbol 
denotes a replicate (n = 4-6) and the median values are indicated by horizontal bars. (B) Depicted 
is the validation of RNA-seq hits via qRT-PCR analysis of significantly differentially expressed 
genes of the complement system. The graphs show the Cy0 values of the indicated genes that 
were normalized to RPL27. Each symbol denotes an independent biological replicate (n = 3) and 
the median values are indicated by horizontal bars. Squares indicate no measured Cy0 value. 
Statistical significances were calculated using unpaired t-tests without Welch’s corrections for 
samples by which a Cy0 value was measured. 
**p < 0.01, ***p < 0.001, ****p ≤ 0.0001; HD, healthy donor; OC, ovarian cancer patient; TPM, transcripts per 
million reads 
The RNA-seq was conducted by the genomics core facility (University Marburg), and the data was analyzed 
by Dr. Florian Finkernagel. 
Another important group showing aberrant regulation is the group of the 
complement factors. C3, CFB, CFI, and C2 were not expressed in healthy donor 
NK cells, but expressed in patient-derived NK cells (Fig. 16A). This could be 
confirmed using qRT-PCR (Fig. 16B). C1S and C1R were also upregulated in 
patient-derived NK cells, but this could not be confirmed by qRT-PCR since 
reliable primers could not be obtained.  
The second pathway that was dysregulated in patient-derived NK cells is the 
Hippo pathway (hsa04390) of which 24 genes showed an altered gene 
expression (Fig. 17A). Genes, that are usually active within the Hippo pathway, 
such as LATS1, LATS2, MOB1A, and MOB1B showed a decreased expression 
in patient-derived NK cells, while genes, which are usually silenced, like YAP1 or 
TEAD4, showed an increased expression (Fig. 17B and C). Furthermore, target 
genes of the Hippo pathway, such as CTGF and AMOTL2, were also expressed 
in ascites-derived NK cells, while they were not expressed in healthy donor NK 
cells (Fig. 17D). However, this did not apply to all potential target genes. AREG 
was higher expressed in the healthy donor NK cells in comparison to the patient-
derived NK cells (Fig. 17D). The results from the RNA-seq could be confirmed 
using qRT-PCR for the target genes analyzed, besides AREG, which did not 
show significant differences (Fig. 17E and F).  
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Fig. 17: Comparison of healthy donor NK cells and ascites-derived ovarian cancer patient 
NK cells by RNA-seq defines dysregulation of the Hippo pathway. 
Identification of differentially expressed genes in healthy donor NK cells (HD) versus ascites-
derived patient NK cells (OC) based on RNA-seq data. Raw reads were aligned to the human 
genome (retrieved from Ensembl 92) using STAR 2.4.1a. Read counts were quantified in exonic 
regions of protein-coding transcripts and normalized to TPM. (A) Depicted is the Venn diagram 
showing the overlap of genes that were upregulated in patient-derived NK cells in comparison to 
healthy donor NK cells, and genes belonging to the Hippo pathway. (B) The Heatmap shows the 
expression of Hippo pathway genes (depicted is the TPM value) that were significantly 
differentially expressed between healthy donor NK cells and ovarian cancer patient NK cells. (C) 
The Scatter plot shows TPM values of YAP1, TEAD1, TEAD2, TEAD3 and TEAD4 and of the 
Hippo target genes AREG, CTGF, and AMOTL2 based on RNA-seq results (D). Each symbol 
denotes a biological replicate (n = 4-6) and the median values are indicated by horizontal bars. 
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(E and F) Validation of RNA-seq hits via qRT-PCR analysis of significantly differentially expressed 
genes of the Hippo pathway (E) and the Hippo target genes (F) was performed. The graphs show 
the Cy0 values of the indicated genes that were normalized to GAPDH or RPL27. Each symbol 
denotes an independent biological replicate (n = 3-7) and the median values are indicated by 
horizontal bars. Squares indicate no measured Cy0 value. Statistical significances were 
calculated using unpaired t-tests without Welch’s corrections for samples by which a Cy0 value 
was measured. 
ns, not significant (p ≥ 0.05), *p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001; HD, healthy donor; OC, 
ovarian cancer patient; TPM, transcripts per million reads  
The RNA-seq was conducted by the genomics core facility (Marburg) and the data was analyzed by Dr. 
Florian Finkernagel.  
Since TEAD4 and the other TEAD family members were exclusively expressed 
in patient-derived NK cells, I focused on the transcription factor TEAD4 and its 
potential coactivators. It has been described that it mainly binds to YAP1, but it 
can also interact with p160 proteins (e.g. NCOA1) and VGLL proteins [128] 
(Fig. 18A). Therefore, the expression of the coactivators was measured. The 
expression of NCOA1 was strongly reduced, while the expression of VGLL1 was 
induced and not expressed in healthy donor NK cells (Fig. 18B and C). 
Furthermore, TEAD4 protein expression was enhanced, as well as a decreased 
NCOA1 expression in patient-derived NK cells (Fig. 18D). Interestingly, YAP1 
was strongly phosphorylated in ascites-derived NK cells, while it was not 
phosphorylated in healthy donor NK cells (Fig. 18D). If YAP1 is phosphorylated, 
it cannot enter the nucleus and induce the expression of target genes. 
Furthermore, it is marked for ubiquitination and can be degraded [253].  
Next, it was investigated, if the ascites is responsible for the downregulation of 
NCOA1 and if it also influences the expression of the transcription factor yin 
yang 1 (YY1), which has been described to act as a repressor on the transcription 
of IFNγ [240]. Indeed, NCOA1 was downregulated in healthy donor NK cells after 
treatment with ascites (Fig. 19A). This was also true for YY1, but it must be noted 
that donor-dependent differences were observed (Fig. 19B). 
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Fig. 18: Expression of TEAD4 binding partners in healthy donor NK cells and ovarian 
cancer patient-derived NK cells. 
(A) Depicted is a schematic representation of TEAD4 binding partners within the nucleus that can 
induce transcription. (B) The Scatter plot shows TPM values of the TEAD4 binding partners 
NCOA1 and VGLL1 based on RNA-seq results. Each symbol denotes a replicate (n = 4-6) and 
the median values are indicated by horizontal bars. Raw reads were aligned to the human 
genome (retrieved from Ensembl 92) using STAR 2.4.1a. Read counts were quantified in exonic 
regions of protein-coding transcripts and normalized to TPM. (C) Validation of RNA-seq results 
via qRT-PCR analysis was performed. Each symbol denotes an independent biological replicate 
(n = 7), and the median values are indicated by horizontal bars. The square indicates no 
measured Cy0 value. Statistical significances were calculated using unpaired t-tests without 
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Welch’s corrections for samples by which a Cy0 value was measured. (D) Depicted is the 
immunoblot analysis of TEAD4, NCOA1 and phosphorylation of YAP1 in healthy donor NK cells 
(HD) and patient-derived NK cells (OC). The right graph shows the quantification of cellular 
NCOA1 level normalized to actin.  
ns, not significant (p ≥ 0.05), **p < 0.01, ****p ≤ 0.0001; HD, healthy donor; OC, ovarian cancer patient; TPM, 
transcripts per million reads 
The RNA-seq was conducted by the genomics core facility (Marburg) and the data was analyzed by Dr. 
Florian Finkernagel.  
In conclusion, using RNA-seq, several pathways dysregulated in tumor-
associated NK cells – including the kegg pathway natural killer cell-mediated 
cytotoxicity and the Hippo pathway – were identified. Furthermore, an induction 
of complement factors was observed. The expression of the components of the 
killer cell-mediated cytotoxicity pathway was mostly reduced and the Hippo 
pathway was turned off, leading to a decreased expression of LATS1 and LATS2, 
and an enhanced expression of YAP1 and TEAD4. While one of the potential 
coactivators of TEAD4, NCOA1, is downregulated and the other one, VGLL1, is 
upregulated.  
Fig. 19: Influence of ascites on the expression of NCOA1 and YY1 in healthy donor NK 
cells. 
Healthy donor NK cells were cultivated for 72 hours in medium or ascites before they were 
analyzed. Depicted is the qRT-PCR analysis of NCOA1 (A) and YY1 (B). Cy0 values of NCOA1 
and YY1 were normalized to RPL27, and relative expression of transcripts from medium-
cultivated or ascites-cultivated NK cells was calculated relative to the freshly isolated untreated 
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NK cells at d0. Each symbol denotes an independent biological replicate (n = 9-10). Statistical 
significances were calculated using paired t-tests. 
*p < 0.05, **p < 0.01; d0, day 0 
3.7 Crosslinking of TGFβ, IL-2 and CD16 induces TEAD4 and 
reduces T-bet expression in healthy donor NK cells  
I have uncovered that TEAD4 is exclusively expressed in patient-derived NK 
cells, but not in healthy donor-derived NK cells. Therefore, the factors inducing 
the expression of TEAD4 in healthy donor NK cells should be identified. Culturing 
of healthy donor NK cells in ascites did not lead to an induction of TEAD4, which 
is probably due to the fact, that the NK cells cannot be cultured for a sufficient 
period of time without dying. Furthermore, culturing NK cells with TAMs or 
monocytes with or without ascites also did not induce TEAD4 expression or 
change any other Hippo target gene expression (e.g. CTGF and AMOTL2).  
So far, little is known about the role of the Hippo pathway in immune cells. 
However, it has been described that YAP1 is expressed in Tregs and that it plays 
an important role in the regulatory function of Tregs. Furthermore, YAP1 
expression in Tregs can be induced by stimulation of naïve T cells with IL-2, TGFβ 
and stimulation of the T cell receptor (TCR) by CD3/CD28 Dynabeads after 4 
days [160]. Therefore, healthy donor NK cells were stimulated with IL-2 and TGFβ 
and together with a strong NK cell activation stimulus for 4 days. As a strong 
activation stimulus, the activation of CD16 by CD16 crosslinking was chosen. 
Indeed, it was observed, that TEAD4 expression was induced upon stimulation 
with all three factors, but not if one of them was missing (Fig. 20A). Furthermore, 
downregulation of NKp30 (Fig. 20B), NKG2D (Fig. 20D) and DNAM-1 were 
observed, but which was mainly induced by the presence of TGFβ. However, 
NKp44 was upregulated upon cultivation with all three stimuli (Fig. 20C). CD16 
was not influenced by the presence of TGFβ but was downregulated after CD16 
crosslinking (data not shown). 
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Fig. 20: Induction of TEAD4 in healthy donor NK cells.  
Healthy donor NK cells were stimulated and cultivated for 96 hours before they were analyzed. 
The cells were stimulated as follows: rNKs (10 U/ml IL-2), IgG and CD16 crosslinking (10 µg/ml 
plate-bound antibody), TGFβ (5 ng/ml), IL-2 (100 U/ml). Freshly isolated NK cells (untreated d0) 
were used as a control. (A) qRT-PCR analysis of TEAD4. Shown are the Cy0 values of TEAD4 
that were normalized to RPL27. Representative data of three independent biological replicates 
were shown. Bar graphs represent means of triplicates ± technical SD. (B-E) Flow cytometry 
analysis of activating receptor expressions on stimulated healthy donor NK cells. Scatter plots 
show the expression of NKp30 (B), NKp44 (C) and NKG2D (D). Each color denotes an 
independent biological replicate (n = 2) and the median values are indicated by horizontal bars. 
rNKs, resting NK cells; crossl., crosslinking; d0, day 0 
A B 
C D 
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Since the NK cell viability decreases with each day of cultivation, a time-course 
experiment to monitor the expression of TEAD4 and cellular viability was 
performed. Here, TEAD4 was already expressed after 24 hours, but the 
expression was further increased after 48 hours and stayed at this level until 96 
hours of stimulation. After 48 hours of stimulation, NK cells still showed 
acceptable viability (data not shown). Hence, for further assays, NK cells were 
stimulated for 48 hours. After 48 hours, ten out of eleven donors showed induction 
of TEAD4 upon stimulation with all three stimuli in comparison to the IgG control 
(Fig. 21A). The median viability of the cells was 93 % for the IgG crosslinked cells 
and 81 % for the CD16 crosslinked cells (Fig. 21B). However, the expression level 
of TEAD4 and the viability of the cells was strongly donor-dependent (Fig. 21). 
Moreover, the expression of other dysregulated genes after treatment with IL-2, 
TGFβ and CD16 crosslinking was analyzed, but no significant changes were 
seen in this setting. Those genes were: YAP1, TEAD1, TEAD2, TEAD3, TRIP6, 
C3, CFB, CFI, and C2.  
Fig. 21: Impact of CD16 crosslinking on the expression of activating receptors.  
Healthy donor NK cells were stimulated and cultivated for 48 hours before they were analyzed. 
The cells were stimulated as follows: IgG and CD16 crosslinking (10 µg/ml plate-bound antibody), 
TGFβ (5 ng/ml), IL-2 (100 U/ml). Freshly isolated NK cells (untreated d0) were used as a control. 
(A) qRT-PCR analysis of TEAD4 was performed. Shown are the Cy0 values of TEAD4 that were 
normalized to RPL27. (B) Depicted is the flow cytometry analysis of the viability of stimulated 
healthy donor NK cells after 48 hours. The scatter plot shows the percentage of viable cells 
A B 
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(Annexin V-/ 7-AAD-), the percentage of apoptotic cells (Annexin V+/ 7-AAD-) and the percentage 
of dead cells (Annexin V+/ 7-AAD). Each symbol denotes an independent biological replicate 
(n = 11-12) and the median values are indicated by horizontal bars. Statistical significances were 
calculated using paired t-tests for samples by which a Cy0 value was measured. 
**p < 0.01; crossl., crosslinking; d0, day 0 
Moreover, it was observed that T-bet (TBX21) expression was reduced in patient-
derived NK cells in comparison to healthy donor NK cells (Fig. 22A and B). T-bet 
is a transcription factor known to drive the differentiation and function of NK cells 
[79] [138]. Therefore, it was studied, if TBX21 is also downregulated in TEAD4-
expressing NK cells. Indeed, it could be confirmed that TBX21 is downregulated 
after TGFβ, IL-2 and CD16 stimulation (Fig. 22C).  
Fig. 22: TBX21 expression in patient-derived NK cells and healthy donor NK cells. 
(A) TBX21 expression in healthy donor NK cells (HD) versus ascites-derived patient NK cells 
(OC) based on RNA-seq data was analyzed. The scatter plot shows TPM values of TBX21. Each 
symbol denotes a replicate (n = 4-6) and the median values are indicated by horizontal bars. (B) 
Validation of RNA-seq results via qRT-PCR analysis of TBX21 was performed. The graphs show 
the Cy0 values of TBX21 that were normalized to RPL27. Each symbol denotes an independent 
biological replicate (n = 2) and the median values are indicated by horizontal bars. (C) Healthy 
donor NK cells were stimulated and cultivated for 48 hours before they were analyzed. The cells 
were stimulated as follows: IgG and CD16 crosslinking (10 µg/ml plate-bound antibody), TGFβ 
(5 ng/ml), IL-2 (100 U/ml). Freshly isolated NK cells (untreated d0) were used as a control. Each 
symbol denotes an independent biological replicate (n = 5-6) and the median values are indicated 
A B C 
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by horizontal bars. Statistical significances were calculated using unpaired t-tests without Welch’s 
corrections. 
**p < 0.01, ***p < 0.001, ****p ≤ 0.0001; HD, healthy donor; OC, ovarian cancer patient; TPM, transcripts per 
million reads; d0, day 0 
The RNA-seq was conducted by the genomics core facility (Marburg) and the data was analyzed by Dr. 
Florian Finkernagel. 
3.8 Crosslinking of TGFβ, IL-2, and CD16 induces TEAD4-
dependent TIM-3 expression in healthy donor NK cells 
Then, I asked how the expression of TEAD4 influences the expression of 
inhibitory receptors and exhaustion markers. After stimulation with IL-2, TGFβ 
and CD16 crosslinking, the KIR CD158a was upregulated, while CD158e was 
strongly downregulated (Fig. 23A). PD-1 was not expressed on stimulated NK 
cells, whereas TIM-3 was strongly induced and TIGIT was higher expressed on 
stimulated NK cells. Nevertheless, this was still lower than the untreated status 
on d0 (Fig. 23B). To investigate, whether the observed changes are indeed 
TEAD4-dependent, the cells were incubated with a TEAD4 inhibitor called 
peptide 17 (P17). This inhibitor disrupts the YAP-TEAD interaction. The co-
incubation with the inhibitor showed a lower expression of TIM-3 than with the 
solvent (Fig. 23C). CD158a did not show any differential expression after 
treatment with the inhibitor. In summary, DNAM-1, NKG2D and NKp30 were 
downregulated by TGFβ alone, while upregulation of TEAD4 and TIM-3 required 
additional CD16 crosslinking. CD158a, CD158e, and TIGIT expression levels 
were changed after TGFβ treatment in combination with CD16 crosslinking. Here, 
CD158e and TIGIT mainly depended on the CD16 crosslinking and CD158a did 
not show differences between TGFβ alone and additional crosslinking in an initial 
experiment (Table 12). 
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Fig. 23: Impact of CD16 crosslinking and TEAD4 expression on the expression of KIRs and 
exhaustion markers.  
Healthy donor NK cells were stimulated and cultivated for 48 hours before they were analyzed. 
The cells were stimulated as follows: IgG and CD16 crosslinking (10 µg/ml plate-bound antibody), 
TGFβ (5 ng/ml), IL-2 (100 U/ml). Freshly isolated NK cells (untreated d0) were used as a control. 
(A-C) Depicted is the flow cytometry analysis of surface marker expression of stimulated healthy 
donor NK cells after 48 hours. Scatter plots show the expression of KIRs (A), markers for 
exhaustion (B) and TIM-3 (C). Additionally, for (C), NK cells were incubated with 40 nM Peptide 17 
(TEAD4 inhibitor) for 30 min at room temperature prior to the stimulation. The inhibitor was 
present for the whole 48 hours of stimulation. Each symbol denotes an independent biological 
replicate (n = 4-8) and the median values are indicated by horizontal bars. Statistical significances 
were calculated using paired t-tests. 
A B 
C 
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*p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001; KIRs, killer-cell immunoglobulin-like receptors; crossl., 
crosslinking; P17, Peptide 17; min, minutes; d0, day 0 
Table 12: Genes influenced by TGFβ or TGFβ and CD16 crosslinking. 
Summary of genes that are affected by either TGFβ treatment alone or in combination with CD16 
crosslinking.  
crossl., crosslinking 
3.9 Crosslinking of TGFβ, IL-2, and CD16 converts healthy 
donor NK cells to an immunosuppressive-like state 
I hypothesized that the TEAD4-expressing NK cells adopt some kind of regulatory 
function and therefore aimed to analyze their functional impact on T cells. In order 
to investigate this hypothesis, NK cells were stimulated to express TEAD4 and 
co-cultured with CFSE-stained T cells for 7 days. The T cells were stimulated to 
induce proliferation. At first, CD3/CD28 Dynabeads at a bead-to-cell ratio of 1:1 
were used to induce the proliferation of CD3 T cells. However, the stimulus was 
too strong to permit an inhibitory effect of the NK cells. Next, CD8+ T cells were 
stimulated with IL-2, IL-7, and IL-15 – a weaker proliferation stimulus. 
Nonetheless, the stimulus was too weak to observe changes. Finally, CD8+ 
CD45RA- CCR7- T cells were sorted, stained with CFSE and co-cultivated with 
the TEAD4-expressing NK cells. They were stimulated with a low CD3/CD28 
bead-to-cell ratio (0.1:1) to induce proliferation. Here it was revealed, that co-
cultivation with TEAD4-expressing NK cells led to diminished T cell proliferation 
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in comparison to co-cultivation with non-TEAD4-expressing NK cells. The 
inhibitor P17 partially reversed this effect (Fig. 24). Nevertheless, it should be 
noted that this effect is highly donor-dependent and requires further investigation.  
Fig. 24: Functional impact of CD16 crosslinking and TEAD4 expression in NK cells.  
Healthy donor NK cells were stimulated and cultivated for 48 hours prior to analysis. The cells 
were stimulated as follows: IgG and CD16 crosslinking (10 µg/ml plate-bound antibody), TGFβ 
(5 ng/ml), IL-2 (100 U/ml). Additionally, NK cells were incubated with 40 nM Peptide 17 (TEAD4 
inhibitor) for 30 min at room temperature prior to the stimulation. The inhibitor was present for the 
whole 48 hours of stimulation. CD8+ CD45RA- CCR7- sorted T cells were co-cultivated with 
stimulated NK cells at the ratio of 1:1 for seven days at 37 °C before the proliferation of the T cells 
was measured using flow cytometry analysis. To induce proliferation, T cells were stimulated with 
CD3/CD28 Dynabeads at a bead to cell ratio of 0.1:1. T cells were stained with CFSE right before 
the stimulation, in order to monitor the proliferation. Displayed are representative data of four 
independent biological replicates. 
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3.10  Identification of potential TEAD4 target genes 
Finally, the gene list of altered genes of patient-derived NK cells vs. healthy donor 
NK cells obtained from the RNA-seq was compared to a gene list containing 
genes with TEAD4 binding sites [132] (Table 13). The TEAD4 binding sites were 
obtained from TEAD4 ChIP-seq analysis, which was performed in the cell lines 
A549, HCT116, SK-N-SH, and ECC1 [132]. For my analysis, genes with TEAD4 
binding sites close to the transcription start site (TSS) were chosen.  
Table 13: Dysregulated genes and potential TEAD4 target genes. 
Comparison of genes, that are altered between patient-derived NK cells and healthy donor NK 
cells identified through RNA-seq and genes, which have TEAD4 binding sites [132]. The distance 
of the TEAD4 binding sites to the TSS is shown in brackets.  
Summing up, I could show that stimulation of healthy donor NK cells with IL-2, 
TGFβ and CD16 crosslinking induces the expression of TEAD4. Moreover, 
TEAD4-expressing NK cells show a TEAD4-dependent upregulation of TIM3 and 
have the capacity to inhibit the proliferation of CD8+ CD45RA- CCR7- T cells. 
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3.11  Summary of main findings 
In brief, in this study, it was demonstrated that NK cells of ovarian cancer patients 
show a mixed tumor-associated phenotype, in which the expression of activating 
receptors, such as DNAM-1, is mostly downregulated and signs of exhaustion, 
such as PD-1 and TIM-3 expression, could be detected. NK cells show an 
impaired effector function, which could be restored by activation with IL-2 and 
IL-15, in combination with blockage of TGFβ signaling. TGFβ in ovarian cancer 
ascites reduces DNAM-1 expression, and a blockage of the TGFβ signaling 
abrogates ascites-mediated downregulation of DNAM-1. Besides, the natural 
killer cell-mediated cytotoxicity pathway and the Hippo pathway were 
dysregulated. Expression of the Hippo pathway protein TEAD4 was exclusively 
detected in patient-derived NK cells and was inducible in healthy NK cells with 
TGFβ, IL-2 and CD16 engagement. TEAD4-expressing NK cells express high 
levels of TIM-3 and inhibited the proliferation of T cells. 
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4 Discussion 
The immune system is essential for the elimination and the control of malignant 
cells. However, in many cancers, the immune system is dysregulated through 
multiple ways leading to impaired immune surveillance [71]. This also applies for 
ovarian cancer [232]. Therefore, it is essential to understand the molecular and 
phenotypical changes of the immune system in the TME of ovarian cancer to 
finally improve immunotherapy options and the outcome of the patients. 
4.1 Novel mechanism of NKG2D-L-mediated immune escape: 
sNKG2D-Ls induce gene expression in NK cells? 
NK cells - as a crucial part of the innate immune system - play a major role in the 
immune surveillance of tumors. One of the best-characterized activating 
receptors of NK cells is the NKG2D receptor, which enables the downstream 
signaling when membrane-associated NKG2D-Ls are engaged. Those ligands 
(e.g. MICA/B, ULBP2) are expressed on malignant or virus-infected cells but are 
absent on healthy cells (Fig. 25A; depicted as a scheme) [179].  
NK cell function of many tumor patients is restricted and the overall results of NK 
cell-based immunotherapy are disappointing. This is often due to tumor-
associated immune escape mechanisms. One described mechanism is the 
shedding of membrane-bound NKG2D-Ls via metalloproteases rendering tumor 
cells invisible for NKG2D-dependent target cell recognition. Moreover, 
sNKG2D-Ls lead to a downregulation of NKG2D and thus impairs NK cell function 
in many epithelial tumors, e.g. lung, breast and colon carcinoma (Fig. 25B; 
depicted as a scheme) [80] [222]. Furthermore, our group showed that in CLL 
and Hodgkin Lymphoma patients the ligands for NKG2D were elevated in the 
serum and are associated with a diminished NKG2D expression and cytotoxicity 
of patient NK cells [183] [184]. 
Interestingly, data of this thesis suggest that the current paradigm of the role of 
the NKG2D-NKG2D-Ls in tumors does not apply to ovarian cancer. In the ascites 
of ovarian cancer patients, high amounts of sMICA and sULBP2 were measured 
and the NKG2D expression on NK cells and T cells was not reduced, but 
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unaltered or even increased. Interestingly, the amount of sNKG2D-Ls positively 
correlated with the accumulation of pro-tumorigenic CD163+CD206+ TAMs and 
reduced memory effector CD4/CD8 T cells [221], which is a novel observation 
and has not been described for other cancers. In mice, Xiao et al. showed that 
sMICB promotes the expansion of MDSCs and that it polarizes macrophages into 
the alternative, immunosuppressive phenotype, via signal transducer and 
activator of transcription 3 (STAT3) activation [234]. Furthermore, it is known that 
NKG2D is expressed on activated murine macrophages [59], while the 
expression of NKG2D on human macrophages is still under debate. Therefore, I 
tested whether human macrophages from healthy donors or ovarian cancer 
patients expressed the NKG2D receptor and could clearly demonstrate that the 
NKG2D receptor expression on human macrophages could not be detected on 
protein or mRNA level (Fig. 1A, B and D). This shows that sNKG2D-Ls from 
ovarian cancer ascites do not directly interact with human macrophages via 
binding to the NKG2D receptor and that the positive correlation of the sNKG2D-L 
levels with the amount of TAMs is based on a different mechanism.  
In mice, Deng et al. observed that NKG2D-Ls on myeloid cells consistently 
stimulate NK cells and thereby induce NKG2D internalization and NK cell 
desensitization (Fig. 25C; depicted as a scheme) [58]. However, the soluble 
NKG2D-L MULT-1 can block this interaction and promote tumor rejection [58]. 
Hence, the NK cells will not be desensitized and can recognize tumor cells via 
other activating receptors (Fig. 25D; depicted as a scheme). In my study, I could 
show that NKG2D-Ls were expressed in human macrophages on mRNA level 
and the expression was enhanced when they were stimulated with LPS 
(Fig. 1E-G). This was in accordance with data from murine macrophages, where 
the NKG2D-L RAE-1 was upregulated after TLR stimulation [86]. Surprisingly, 
MICA and MICB were not detected on the surface of human healthy donor 
macrophages and ovarian cancer TAMs (data not shown). Moreover, ULBP2 was 
weakly expressed on the surface of human healthy donor macrophages (data not 
shown), while some ovarian cancer patients (2/3) revealed a robust expression 
of ULBP2 on TAMs (Fig. 1H). In our setting, the fold induction of NKG2D-Ls was 
between two- to four-fold (Fig. 1E-G), which is much lower in comparison to work 
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from Hamerman et al. in which murine macrophages displayed a 30-50-fold 
RAE-1 induction after LPS treatment [86]. Furthermore, the highest measured 
normalized Ct value of the NKG2D-Ls was 27 and many Ct values were close to 
the detection limit (Table S1-S3). The low mRNA expression levels of NKG2D-Ls 
and the low surface expression of NKG2D-Ls suggest that NKG2D-L expression 
of macrophages might not have a major functional impact.  
In line, the killing of macrophages was not NKG2D-dependent (Fig. 3). Zhou et 
al. showed, that murine polyriboinosinic-polyribocytidilic acid (poly I:C)-treated 
macrophages activated NK cells via NKG2D, but protected themselves from 
killing via expression of Qa-1, the ligand for the inhibitory receptor NKG2A [255]. 
A possible upregulation of inhibitory or protecting receptors on macrophages was 
not addressed in this thesis. 
Taken together, human healthy donor macrophages and ovarian cancer TAMs 
do not express the NKG2D receptor, but on mRNA level, they express the 
NKG2D-Ls MICA, MICB and ULBP2. Nonetheless, only ULBP2 was detected on 
their surface. However, the killing of macrophages is not NKG2D-dependent. 
High amounts of sNKG2D-Ls in ovarian cancer ascites correlate with a short 
relapse free survival of patients, an increased amount of TAMs and a reduced 
accumulation of memory effector T cells. However, the NKG2D expression on NK 
cells and T cells is not reduced. This demonstrates that the function of 
sNKG2D-Ls in ovarian cancer is more complex than initially thought. Here, they 
do not carry out their known function, but rather display additional, yet unknown 
functions that need to be investigated further. 
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Fig. 25: NKG2D-NKG2D-L – mediated NK cells activation. 
(A) NKG2D-NKG2D-L – mediated NK cell activation, leads to the release of perforin and 
granzyme and therefore, to the elimination of the tumor cells. (B) sNKG2D-Ls compete with 
mNKG2D-L for the binding to the NKG2D receptor. Hence, sNKG2D-Ls prevent mNKG2D-L 
binding to the receptor, NKG2D receptors are internalized and tumor cells are not eliminated. (C) 
NK cells are activated via NKG2D-NKG2D-L interaction, leading to the release of perforin and 
granzyme and therefore, to the lysis of the TAM. Furthermore, this leads to the desensitization of 
the NK cells, in which NKG2D receptors are being internalized. Thereby, TAMs are shielding 
tumor cells against the recognition and elimination by NK cells. (D) sNKG2D-Ls compete with 
mNKG2D-L for the binding to the NKG2D receptor. Hence, sNKG2D-Ls prevent mNKG2D-L 
A B 
C D 
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binding to the receptor and desensitization of the NK cells. NK cells are then able to kill tumor 
cells via signaling of other activation receptors.  
TME, tumor microenvironment; TAMs, tumor-associated macrophages; sNKG2D-Ls, soluble NKG2D 
ligands; mNKG2D-L, membrane-bound NKG2D ligands 
4.2 Soluble ULBP2 alters gene expression of tumor-related 
genes 
Since sNKG2D-Ls from the ovarian cancer ascites did not induce NKG2D 
internalization in NK cells [221] and did not influence the killing of macrophages 
(Fig. 2 and 3), I hypothesized that, the function of the ligands depends on different 
mechanisms.  
To test whether sNKG2D-Ls act via NKG2D-dependent signaling, RNA-seq was 
used to identify different target genes of NKG2D induced by the engagement of 
mNKG2D-Ls and sNKG2D-Ls. Here, ten mULBP2-specific target genes and 
twelve sULBP2-specific target genes were identified, respectively (Table 10).  
Among the mULBP2-specific target genes were known target genes for 
mNKG2D-Ls, like CD69 or TNF, showing that the method itself is valid. CD69 is 
an unspecific, early activation marker that is induced by various stimuli, such as 
IL-2, phorbol 12-myristate 13-acetate (PMA) or IFN-α [21]. More importantly, it is 
also induced upon engagement of NKG2D-Ls expressed by macrophages and 
DCs with NKG2D on NK cells [207]. It triggers NK cell-mediated cytotoxicity, 
proliferation and induces the expression of CD25 and TNF-α secretion, which can 
be abolished by CD94 stimulation [21]. Moreover, ULBP2 was detected, which 
was overexpressed on S2 cells present in the culture. This serves as an internal 
control. RAET1L (ULBP6) was also found, sharing a 97% sequence identity with 
ULBP2 [61]. Furthermore, transcription factors like c-fos (FOS), which are known 
to play a role in NK cell activation, were induced [175]. Interestingly, the nuclear 
orphan receptor NR4A2 was one of the hits, which is poorly investigated in NK 
cells. Sekiya et al. demonstrated that ectopic expression of NR4A2 in naïve CD4+ 
T cells conveyed Treg functions by inducing the expression of Foxp3 and by 
inhibition of IL-2 and IFNγ production [191]. In NK cells, NR4A2 expression was 
increased after CD16-stimulation [164].  
Discussion  102 
 
All of the genes identified as targets for sNKG2D-Ls play a described role in 
cancer and are used or discussed as therapeutic targets. Moreover, RNA-seq 
data revealed that two out of ten of the sNKG2D-L-induced target genes in NK 
cells were also significantly higher expressed in ovarian cancer TANKs and these 
are CEMIP and NXPH4 (data not shown). However, only four out of the twelve 
sNKG2D-specific target genes have been described in NK cells so far. Those 
genes are CXCL8, IL1B, INHBA and CLEC4E. While CXCL8 and IL-1β play a 
role in NK cell homeostasis and differentiation [94] [151], INHBA and CLEC4E 
have been exclusively described in uterine NK cells [69] [73].  
CEMIP encodes a protein that induces cell migration and is associated with 
carcinogenesis. Shen et al. showed that CEMIP expression in ovarian cancer 
tissue is increased and that silencing of CEMIP resulted in reduced cell 
proliferation and cell migration of ovarian cancer cell lines [192]. However, a role 
of CEMIP in NK cells has not been described so far. 
ACOD1 (also known as IRG1, which encodes the aconitate decarboxylase 1), 
CLEC4E (also referred as Mincle) and PLA2G7 were identified as novel target 
genes after sNKG2D-L engagement (Table 10; Fig. 5). The expression of ACOD1 
was shown to play a role in murine macrophages. Here, ACOD1 was upregulated 
after the stimulation with various cytokines, such as IFNγ, or TLR agonists, such 
as LPS or CpG. Furthermore, it is associated with mitochondria [56]. It was 
demonstrated, that the enzyme encoded by ACOD1 decarboxylates cis-aconita 
and thereby catalyzes the production of itaconic acid. Itaconic acid inhibits 
isocitrate lyase of bacteria and thereby prevents its growth [149]. Moreover, 
itaconic acid promotes tumor growth in various cancer types [163] [229]. About 
ACOD1 expression in NK cells nothing is known so far, but it would be interesting 
to study the role of ACOD1 in the context of NKG2D signaling and ovarian cancer. 
CLEC4E is a type II transmembrane c-type lectin receptor that is upregulated in 
macrophages after stimulation with LPS, IL-6, TNF-α or IFN-γ [144]. Decidual NK 
(dNK) cells of women with multiple pregnancies show a specific phenotype, in 
which NKG2C is highly expressed. Those pregnancy-trained decidual NK cells 
show enhanced expression of CLEC4E [73]. In fact, tumor infiltrating NK cells 
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show a similar phenotype than dNK cells, e.g. they express VEGF and promote 
angiogenesis [85] [123], suggesting a possible role of CLEC4E in TANKs as well. 
However, the function of CLEC4E in human NK cells is still elusive.  
Finally, Low et al. showed that PLA2G7 expression in human macrophages was 
induced after co-cultivation with different tumor cell lines and that secreted 
PLA2G7 induced the migration of the tumor cells [135]. Moreover, PLA2G7 is 
associated with early relapse in HGSOC [181]. Again, PLA2G7 expression in NK 
cells has not been described so far.  
Taken together, I demonstrated for the first time that engagement of NKG2D 
receptor by soluble ligands induces changes in gene expression. All of them with 
reported overexpression or function in tumor pathogenesis. Besides CXCL8 and 
IL1B, little is known about the role of those genes including ACOD1, CLEC4E, 
and PLA2G7 in NK cells.  
4.3 Ovarian cancer NK cells display a mixed tumor-associated 
phenotype  
NK cells play a crucial role in the recognition and elimination of tumor cells. It is 
published that the expression of activating and inhibitory receptors of NK cells is 
altered in ovarian cancer, but in general not much is known about the phenotype 
of tumor-associated NK cells in ovarian cancer [14] [36] [66] [111] [221]. 
Furthermore, those studies analyzed only small cohorts with mostly less than ten 
patients included. Therefore, the aim of this thesis was to characterize NK cells 
of ovarian cancer patients on a molecular and functional level in a larger cohort, 
in order to discover novel potential target sites.  
Patient-derived NK cells exhibited a phenotype, in which the expression of CD56 
was high and the expression of CD16 was low (Fig. 6). This is in line with previous 
findings by Belisle et al. in which 40 % of the peritoneal fluid NK cells displayed 
the CD56bright CD16- phenotype [14]. Furthermore, this was also confirmed by 
Carlsten et al. [36].  
Besides NKG2D, NKp46, and CD69, all activating receptors were downregulated 
on ascites-derived NK cells, from which NKp44 and DNAM-1 were the strongest 
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affected (Fig. 7 and 8). The expression of NKG2D was even upregulated, which 
is contrary to previously described data, in which the expression of NKG2D was 
not altered or even decreased (Fig. 7) [14] [111] [221]. Conversely, Carlsten et 
al. observed an increased NKG2D expression on ascites-derived NK cells [36]. 
Overall, the NKG2D expression among the patients strongly varied and some 
patients also displayed a decrease in NKG2D expression (Fig. 7). However, it 
must be taken into account that average blood donors are younger than ovarian 
cancer patients [97] [256]. In order to rule out the effect of age and gender on the 
expression of the surface molecules, donors were gender- and age-matched. 
Moreover, these data represent one of the biggest cohorts so far (up to 68 ascites 
samples measured). The observed differences can be probably attributed to the 
smaller sample size (mostly less than 10 samples) analyzed without gender- and 
age-match. 
Regarding inhibitory receptors, the results were mixed. NKG2A was upregulated 
(Fig. 7), while CD158e was strongly downregulated (Fig. 9). In breast cancer, it 
was already demonstrated that NKG2A was upregulated on NK cells and that this 
correlated with an impaired NK cell function [139]. Currently, treatment with 
monalizumab, an antibody against NKG2A, in combination with an anti-PD-L1 
treatment, shows promising results to restore NK cell function [6]. Reduced 
CD158e expression corroborates with previously described data [14] [66]. 
Moreover, the NK cells exhibited an exhausted phenotype, as PD-1 and TIM-3 
expression was increased (Fig.10). In multiple myeloma patients, NK cells 
expressed PD-1 and inhibition of the PD1/PD-L1 signaling axis led to a restored 
NK cell function [17]. In addition, in ovarian cancer patients, Matsuzaki et al. 
showed that PD-1 is expressed on CD8+ T cells of the patients leading to an 
impaired effector function [145]. Hence, targeting the PD1/PD-L1 signaling axis 
in ovarian cancer may revive the NK cell and CTL effector functions.  
In addition, ascites-derived NK cells showed a reduced cytotoxic capacity against 
K562 target cells. However, this effect was reversible, when the NK cells were 
stimulated with IL-2 and IL-15 and they were no longer influenced by the ascites 
(Fig. 11). Lutgendorf et al. published that ascites-derived NK cells display a 
diminished cytotoxic potential and that this is further reduced by psychological 
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distress [137]. This was confirmed by findings of Carlsten et al.; here cytotoxicity 
of TANKs was reduced by half in comparison to peripheral blood NK cells of the 
patients [36]. 
Summing up, ovarian cancer patient-derived NK cells display a tumor-associated 
phenotype, in which most of the activating receptors are downregulated and the 
NK cells are exhausted (shown by the upregulation of PD-1, TIM-3, and NKG2A 
expression). Moreover, they show a reduced cytotoxic potential against target 
cells. Nevertheless, their function can be restored by treatment with IL-2 and 
IL-15 and by depletion of the ascites. It still needs to be investigated which factor 
(or factors) from ascites inhibits the NK cell functions. In this thesis, I showed that 
one of these factors is TGFβ (see section 4.4). For clinical applications, treatment 
with anti-PD-1 and/or anti-NKG2A may improve the clinical outcome of the 
patients, but further experiments in this direction are needed.  
4.4 TGFβ from ascites contributes critically to the tumor-
associated NK cell phenotype 
Cultivation of healthy donor NK cells in ovarian cancer ascites inhibits NK cell 
cytotoxicity (Fig. 12E and F).  
TGFβ is described to be a key player involved in immune evasion. It inhibits NK 
cells by downregulating various activating receptors, such as NKp30, NKG2D 
and DNAM-1 [83] [231]. Moreover, TGFβ1 is enriched in ovarian cancer ascites 
and was associated with a short RFS [181]. Hence, it was observed that TGFβ1 
decreased DNAM-1 expression and that blocking of the TGFβ signaling 
enhanced the expression. Furthermore, the cultivation of healthy donor NK cells 
in ascites reduced the DNAM-1 expression, which could be partially restored by 
blocking TGFβ signaling. Interestingly, the anti-TGFβ antibody was more efficient 
than the TGFβ receptor kinase inhibitor under the conditions chosen here 
(Fig. 13). Moreover, the effect on mRNA level was stronger than on protein level, 
which could be due to a longer half-life of the protein. 
Furthermore, if the TGFβ signaling pathway in ascites-derived NK cells is blocked 
and the cells are cultivated in medium, then the cytotoxic capacity of the NK cells 
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could be almost fully restored (Fig. 14B). This was associated with a higher 
DNAM-1 expression on the NK cells (Fig. 14C). However, the cytotoxic potential 
of the NK cells cultivated in the ascites could not be completely restored, hinting 
at a limitation of the blocking reagent and/or other important factors within the 
ascites influencing the cytotoxicity of NK cells. In hepatocellular carcinoma, it was 
shown, that fibroblasts produce prostaglandin E2 (PGE2) and indoleamine 2,3-
dioxygenase (IDO), which are responsible for NK cell dysfunction by 
downregulating NKG2D and NKp30 expression [125]. Furthermore, Martinet et 
al. demonstrated that PGE2 binds to E-prostanoid 2 (EP2) and EP4 receptors on 
NK cells and thereby inhibits its NKG2D-, NCR- and CD16-mediated activation 
[142]. PGE2 plasma levels from ovarian cancer patients are enriched in 
comparison to healthy controls [212]. Hence, PGE2 could be one of the additional 
factors, which influence the cytotoxicity of NK cells in ovarian cancer. Future 
experiments to address this question could include neutralization of PGE2 in the 
ascites and the analysis of NK cell effector function. Moreover, NK cells could be 
activated via NKG2D and CD16 and treated with purified PGE2. Here, the 
activation of the NK cells should be blocked. 
4.5 RNA-seq reveals dysregulation of various pathways in 
ovarian cancer NK cells 
I have seen that the NK cells of ovarian cancer patients show a mixed tumor-
associated phenotype, in which their function is impaired (Fig. 6-11). However, 
they are not suppressed by conventional inhibition strategies, such as 
downregulation of NKG2D by sNKG2D-Ls (Fig. 7) [221]. Therefore, global 
analysis of tumor-associated NK cells is required to understand their function in 
ovarian cancer and thus, to identify novel potential target sites.  
Here, RNA-seq was performed and the gene expression profile of ascites-derived 
NK cells was compared to healthy donor-derived NK cells. I identified two 
important pathways being dysregulated in patient-derived NK cells – the kegg 
pathway natural killer cell-mediated cytotoxicity (Fig. 15) and the Hippo pathway 
(Fig. 17). Surprisingly, factors of the complement system were also expressed in 
patient-derived NK cells, while they were completely absent in healthy donor NK 
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cells (Fig. 16). Activation of the complement system has been shown to play a 
role in promoting tumor growth and metastasis [1]. However, they have not been 
described to be expressed by NK cells and therefore it would be interesting to 
further characterize the function of the complement factors in NK cells.  
Components of the natural killer cell-mediated cytotoxicity pathway that were 
downregulated were for example, FCGR3A (CD16), VAV1 or CD226 (DNAM-1) 
(Fig. 15). This was in agreement with previous experiments of this thesis in which 
CD16 expression of patient-derived NK cells was strongly reduced 
(Fig. 6C and D), as well as the DNAM-1 expression (Fig. 8). VAV1 was shown to 
be an effector molecule, that together with growth factor receptor bound protein 2 
(Grb2) binds to DAP10, initiates tyrosine-phosphorylation and downstream 
signaling of NKG2D [214]. Hence, VAV1 is required for NKG2D-mediated 
cytotoxicity of NK cells and confirms the finding that patient-derived NK cells 
showed an impaired cytotoxic potential (Fig. 11). 
Unexpectedly, the expression of Hippo pathway genes was altered. In ovarian 
cancer, it was demonstrated that YAP overexpression in cancer cells can transmit 
chemoresistance and that high amounts of nuclear YAP are associated with a 
poor prognosis [250]. So far, little is known about the role of the Hippo pathway 
in immune cells. Thaventhiran et al. revealed that activation of CD8+ T cells by 
stimulation with IL-2 and with antigen-stimulation induced the expression of Hippo 
pathway components (such as SAV1, LATS1, MOB1, TEAD1, and TEAD3), 
which induced YAP degradation and Blimp-1 expression required for terminal 
differentiation of T cells [211]. In macrophages, YAP binds to IRF3 and thereby 
prevents its dimerization and translocation to the nucleus, leading to the blockage 
of the antiviral immune response of macrophages [225].  
Here, I report the first evidence for a role of the Hippo pathway in NK cells. The 
expression of LATS1 and LATS2, as well as MOB1B, which are important 
regulators of the Hippo pathway, were downregulated in patient-derived NK cells. 
Conversely, YAP1 and the TEAD family members were upregulated (Fig. 17). 
Among the TEADs, TEAD4 showed the highest significance and lowest variation 
within the RNA-seq. This shows, that the Hippo pathway in ascites-derived NK 
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cells is turned off, YAP can translocate to the nucleus and together with TEAD4 
activate YAP/TEAD-dependent target gene transcription. In agreement with this, 
the classical Hippo target genes CTGF and AMOTL2 were upregulated in patient-
derived NK cells. Interestingly, the expression of AREG was downregulated 
(Fig. 17D and F). However, AREG was the only target gene that was already 
expressed in healthy donor-derived NK cells, hinting to an additional, Hippo-
independent role of AREG in NK cells. It was described, that AREG is expressed 
in type 2 innate lymphoid cells (ILC2s) after stimulation with IL-25, IL-33 and 
thymic stromal lymphopoietin (TSLP) and that it plays an important role in tissue 
homeostasis following influenza infection [153] [203]. 
TEAD4 is mainly known to interact with YAP, but it can also bind to VGLLs and 
p160 proteins (Fig. 18A) [128] [12]. Surprisingly, YAP was phosphorylated in 
ascites-derived NK cells (Fig. 18D), implying for a YAP-independent role of 
TEAD4. Furthermore, the expression of NCOA1 (belonging to the p160 proteins) 
was reduced in patient-derived NK cells, while the expression of VGLL1 was 
induced (Fig. 18). Moreover, the expression of NCOA1 in healthy donor NK cells 
could be diminished by cultivation in ascites (Fig. 19). Thus, VGLL1, instead of 
YAP and NCOA1, can be the potential coactivator of TEAD4 in NK cells of ovarian 
cancer patients.  
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Conclusively, these are the first data providing evidence for a role of the Hippo 
pathway, especially TEAD4 and possible target genes, such as CTGF and 
AMOTL2, in human NK cells (Fig. 26).  
Fig. 26: Hippo pathway in ascites-derived NK cells. 
LATS1/2 and MOB1 are downregulated in patient-derived NK cells. However, YAP is still 
phosphorylated and can probably not enter the nucleus. Conversely, VGLL1 is upregulated and 
can potentially bind to TEAD4 to induce target gene expression. The classical Hippo target genes 
CTGF and AMOTL2 are upregulated. Further possible target genes of TEAD4 are HAVCR2, 
TBX21, and TGM2.  
Red: downregulated in patients; green: upregulated in patients; grey: not altered  
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4.6 Cutting edge: TEAD4 expression is inducible in healthy 
donor NK cells 
Based on the data, the next aim of this thesis was to identify factors that are 
responsible for the TEAD4 expression in NK cells. However, incubation of healthy 
donor NK cells with ascites fluid was not sufficient to induce TEAD4 expression. 
Similarly, cultivation of healthy donor NK cells with patient-derived peritoneal cells 
or TAMs with or without ascites did not induce TEAD4 expression (data not 
shown). I hypothesized that the culture duration was too short to see a TEAD4 
induction, but the NK cells could not be maintained in ascites for longer than four 
days due to strongly diminished viability.  
Furthermore, it was shown that S1P and LPA reduce the phosphorylation of YAP 
by turning off the Hippo pathway in ovarian cancer cells [33] [65]. LPA levels in 
ovarian cancer ascites are increased and correlate with short RFS [182]. 
Nevertheless, LPA did not induce expression of TEAD4 in healthy donor NK cells.  
In general, many signaling pathways influence the expression of TEAD4. 
However, I have already demonstrated that TGFβ from ovarian cancer plays an 
important role on NK cell function by influencing the expression of DNAM-1 and 
reducing NK cell cytotoxicity (Fig. 13 and 14). Furthermore, Ni et al. demonstrated 
that naïve T cells can be stimulated with IL-2, TGFβ and via TCR stimulation for 
four days to induce the expression of YAP. In turn, YAP facilitates FOXP3 
expression and Treg differentiation [160]. Since NK cells do not express the TCR, 
I stimulated them with IL-2, TGFβ and CD16, which was used as a target to mimic 
a strong activation. Moreover, like the TCR of T cells, CD16 associates with the 
CD3ζ chain and thereby induces activation [113]. Indeed, only the combination 
of all three stimuli increased the expression of TEAD4 (Fig. 20A). Furthermore, 
NKG2D and NKp30 expression were reduced by TGFβ without the need for CD16 
crosslinking. NKp44 did not show clear results (Fig. 20B, C and D) and further 
investigations are needed. This is in agreement with previous data, in which 
TGFβ downregulated the expression of activating receptors, such as NKG2D, 
NKp30 and DNAM-1 (this work, Fig. 20) [83] [231]. Indicating that TGFβ, IL-2 and 
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CD16 activation are the putative physiological stimuli within the ascites inducing 
a TEAD4-expressing phenotype. 
Nevertheless, the longer the NK cells were maintained in culture, the lower their 
viability was. Therefore, a time-course experiment was performed to determine 
the optimal culture duration. The optimal culture time was set at 48 hours due to 
the highest expression of TEAD4 and acceptable viability of the NK cells (over 
80 %). Here, 11 out of 12 donors showed a TEAD4 induction (Fig. 21A). However, 
it must be noted that the level of TEAD4 expression was strongly donor-
dependent and sometimes close to the detection limit. Hence, further stimuli 
and/or a longer stimulation time are required to further increase TEAD4 
expression, in order to reach the expression level of tumor-associated NK cells. 
Moreover, YAP1 could not be induced using this system, again hinting to a YAP-
independent role of TEAD4. Interestingly, I provide the first evidence that TEAD4 
can be induced in healthy donor NK cells by the potential physiological stimuli 
TGFβ, IL-2 and through CD16 activation. 
Furthermore, patient-derived NK cells downregulated TBX21 (Fig. 22A and B). 
TBX21 encodes the transcription factor T-bet, which is a master regulator of the 
effector functions of T cells [198]. Human NK cells constitutively express T-bet 
and it is necessary for the differentiation of peripheral blood NK cells. T-bet 
expression is reduced during exhaustion and low levels of T-bet are associated 
with a compromised anti-tumoral NK cell function [79] [138]. Stimulation of 
healthy donor NK cells with TGFβ, IL-2 and CD16 crosslinking diminished the 
TBX21 expression (Fig. 22C), again hinting at an exhausted NK cell phenotype 
with an impaired effector function. 
4.7 TEAD4 promotes TIM-3 expression and a regulatory NK cell 
phenotype 
The last aim was to unravel the function of TEAD4 in NK cells. It was observed 
that the expression of CD158a and TIM-3 was induced on NK cells stimulated to 
express TEAD4, while the expression of CD158e was reduced (Fig. 23). This 
partially mimics the pattern observed in patient-derived NK cells, where TIM-3 
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expression was increased and CD158e was downregulated. CD158a, 
conversely, was not altered in patient-derived NK cells (Fig. 9 and 10). Next, I 
investigated whether the observed changes were indeed TEAD4-dependent. 
Thus, by using the YAP-TEAD inhibitor P17, which disrupts the YAP-TEAD 
interaction, I confirmed that the expression of TIM-3 was TEAD4-dependent 
(Fig. 23C). Moreover, the TIM-3 promotor contains TEAD4 binding sites hinting 
at a TEAD4-dependent TIM-3 gene regulation [132]. The expression of CD158a 
and CD158e was not altered upon treatment with the inhibitor, pointing to a 
TEAD4-independent regulation. To support the findings and rule out the 
possibility that this is due to side effects of the inhibitor, additional experiments 
with a second inhibitor and a genetic knock-out of TEAD4 are required. Therefore, 
the well-established inhibitor verteporfin, which prohibits the association of YAP 
with TEAD, was tested, but it was inapplicable due to high autofluorescence of 
the compound. Thus, a genetic knock-out of TEAD4 is required to formally proof 
the causal link of TEAD4 induction and TIM-3 expression. 
I hypothesized that tumor-associated NK cells in ovarian cancer may correspond 
to regulatory NK cells, e.g. reflected by their capability to suppress T cell activity, 
which are suppressed in ovarian cancer [232]. If TEAD4-expressing NK cells 
exhibit a regulatory phenotype, they should inhibit the proliferation of T cells. 
Therefore, TEAD4-expressing NK cells were co-cultivated with CFSE-labeled, 
stimulated T cells. Indeed, in 4 out of 6 donors, TEAD4-expressing NK cells 
inhibited the proliferation of the T cells (Fig. 24). Nevertheless, it must be noticed 
that the experiment is challenging. The assay worked best, if not all CD3+ T cells 
were used, but a subtype of T cells, the CD8+ TEM cells, was employed. Moreover, 
the proliferation stimulus should not be too strong (high CD3/CD28 beads-to-cell 
ratio) or too weak (cytokine stimulation), since otherwise no inhibitory effects were 
detected. Finally, the magnitude of T cell inhibition was strongly donor-
dependent. Hence, in order to validate the data, the assay should be conducted 
using genetic models, such as TEAD4 negative NK cells.  
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4.8 Future perspectives 
Ovarian cancer ascites is a unique model for the analysis of immune cells in the 
TME. The functional and molecular characterization of tumor-associated NK cells 
in ovarian cancer revealed that target recognition and target cell killing was 
severely impaired. This correlated with an aberrant expression of molecules 
involved in the kegg pathways natural killer cell-mediated cytotoxicity and the 
Hippo pathway. 
This thesis provides first evidence that TEAD4-expressing NK cells exert NK cell 
regulatory functions and are able to inhibit the proliferation of T cells. The effect 
on macrophages and NK cells themselves remains elusive. This could be 
investigated by measuring the ADCC of macrophages or NK cells with the 
presence or absence of TEAD4-expressing NK cells. 
Moreover, the effects of TEAD4 on a molecular level have to be studied. In order 
to identify TEAD4 target genes, I already compared my RNA-seq list of 
differentially expressed genes from patient-derived NK cells vs. healthy donor NK 
cells, to a gene list containing TEAD4 binding sites [132]. Here, a list of seven 
potential candidates (Table 13) was identified. Currently, the promoter and 
enhancer regions of TIM-3 and TGM2 are cloned into luciferase reporter 
constructs to analyze TEAD4-dependent gene transcription. Next, TEAD4 
binding sites will be mutated to validate their functional role. 
In parallel, gain and loss of function experiments for TEAD4 in NK cells are 
planned. TEAD4 will be lentivirally transduced into primary NK cells to analyze 
whether this is sufficient to induce the TANK phenotype. Vice versa, TEAD4 will 
be silenced via CRISPR-Cas9 to investigate whether TEAD4 is necessary for the 
generation of the TGFβ/IL-2/CD16-induced TANK phenotype. To establish the 
system, the NK cell lines NK92 and NKL will be used.  
These cell lines, e.g. TEAD4-overexpressing or TEAD4-deficient NK92 cells, can 
be used for in vivo mouse experiments. Their role in tumor progression will be 
analyzed upon transplantation in xenograft ovarian cancer mouse models. 
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4.9 Conclusions 
NK cells of ovarian cancer patients show a mixed tumor-associated phenotype, 
in which most of the activating receptors are downregulated and signs of 
exhaustion can be detected. They show an impaired NK cell effector function, 
which can be restored by activation with IL-2 and IL-15, together with a blockage 
of TGFβ. Here, the first evidence for a role of the Hippo pathway in NK cells is 
provided, since RNA-seq identified a dysregulation of the Hippo pathway. 
TEAD4, a Hippo pathway protein, is highly expressed in ovarian cancer patient-
derived NK cells, while the expression is completely absent in healthy NK cells. 
In addition to that, TGFβ, IL-2 and CD16 crosslinking induced the expression of 
TEAD4 in healthy NK cells and triggered TEAD4-dependent TIM-3 expression 
(see Fig. 27 as a model). NK cells gained a regulatory function, in which they 
were able to suppress T cell proliferation. These findings shed more light on the 
role of NK cells in the TME of ovarian cancer patients. Additional research will 
increase our knowledge of NK cell tumor surveillance, paving the way for 
strategies boosting anti-tumor NK cell functions.  
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Fig. 27: Model of TANKs in ovarian cancer ascites. 
TANKs showed a downregulation of the activating receptors DNAM-1 and CD16, while NKG2D 
was upregulated (depicted in green). Soluble ULBP2 engaged NKG2D and induced target gene 
transcription. Co-inhibitory receptors PD-1 and TIM-3 were upregulated (marked in red). IL-2, 
TGFβ and CD16 stimulation induced TEAD expression, which in turn potentially activates the 
transcription of TIM-3, TGM2 and TRIP6. Subsequently, these alterations lead to a reduced 
cytotoxicity and a reduced cytokine release of the TANKs. 
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Appendix 
Table S1: Normalized Ct values of MICA. 
Shown are the normalized Ct values of MICA of each donor and each treatment used in Fig. 1E. 
The mean RPL27 Ct of all donors and all treatments was calculated and added to the Δ Ct values 
(MICA - RPL27) of each condition. The mean RPL27 Ct value was 20,93.  
donors untreated + 24 h LPS + 48 h LPS + 72 h LPS 
Sp1 22.11.16 28,64 27,23 26,83 27,40 
Sp2 22.11.16 28,08 27,07 27,00 27,17 
Sp1 24.11.16 28,26 27,27 26,83 27,60 
Sp2 24.11.16 31,63 31,15 30,98 31,78 
Sp1 04.01.17 27,73 27,03 26,98 26,81 
Sp2 04.01.17 28,88 27,80 27,53 27,90 
Sp3 04.01.17 34,26 33,26 33,51 33,01 
 
Table S2: Normalized Ct values of MICB.  
Shown are the normalized Ct values of MICB of each donor and each treatment used in Fig. 1F. 
The mean RPL27 Ct of all donors and all treatments was calculated and added to the Δ Ct values 
(MICB - RPL27) of each condition. The mean RPL27 Ct value was 20,93.  
donors untreated + 24 h LPS + 48 h LPS + 72 h LPS 
Sp1 22.11.16 29,19 27,11 27,18 27,16 
Sp2 22.11.16 28,54 27,37 27,43 28,05 
Sp1 24.11.16 30,10 28,23 27,92 28,74 
Sp2 24.11.16 29,40 28,89 28,37 29,04 
Sp1 04.01.17 31,03 29,73 30,33 29,55 
Sp2 04.01.17 31,53 29,39 30,18 30,47 
Sp3 04.01.17 30,95 28,87 30,45 30,03 
  
Table S3: Normalized Ct values of ULBP2. 
Shown are the normalized Ct values of ULBP2 of each donor and each treatment used in Fig. 1G. 
The mean RPL27 Ct of all donors and all treatments was calculated and added to the Δ Ct values 
(ULBP2 - RPL27) of each condition. The mean RPL27 Ct value was 20,93.  
donors untreated + 24 h LPS + 48 h LPS + 72 h LPS 
Sp1 22.11.16 32,82 32,57 32,11 32,05 
Sp2 22.11.16 31,16 30,85 30,52 30,72 
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Sp1 24.11.16 32,28 31,42 31,02 31,26 
Sp2 24.11.16 32,41 32,01 31,57 31,57 
Sp1 04.01.17 33,95 32,27 32,53 37,78 
Sp2 04.01.17 30,02 30,04 30,00 30,97 
Sp3 04.01.17 33,49 33,22 35,73 38,84 
 
Table S4: TPM values of mULBP2 target genes. 
 Sp1 20.02.19 NKs 
Genes IL-2 + IL-15 sULBP2 S2 WT cells S2 ULBP2 cells 
CCR6 9,7 8,98 8,41 2,26 
CD69 258,97 239,64 527,58 1379,12 
EGR1 17,62 20,72 12,45 51,46 
FOS 4,68 4,74 7,42 19,02 
NR4A2 10,98 8 29,15 99,47 
RAET1L 4,15 4,35 2,81 709,8 
TNF 201,6 202,8 122 456,56 
TNFRSF9 21,5 16,08 30,52 65,11 
TNFSF9 2,7 3,11 2,7 16,55 
ULBP2 11,76 10,97 9,44 319,16 
 
 Sp1 07.06.19 NKs 
Genes IL-2 + IL-15 sULBP2 S2 WT cells S2 ULBP2 cells 
CCR6 9,67 9,89 13,38 7,4 
CD69 155,35 161,49 270,12 905,77 
EGR1 11,97 11,48 7,02 38,87 
FOS 2,6 2,95 4,5 16,85 
NR4A2 5,64 5,22 7,92 37,59 
RAET1L 3,69 2,63 4,62 267,3 
TNF 166,11 127,85 173,65 448,89 
TNFRSF9 9,23 6,01 6,75 20,9 
TNFSF9 1,41 1,66 0,69 7,32 
ULBP2 9,07 7,16 9,31 129,43 
 
 Sp1 24.06.19 NKs 
genes IL-2 + IL-15 sULBP2 S2 WT cells S2 ULBP2 cells 
CCR6 3,7 3,31 3,17 1,54 
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CD69 269,86 362,79 265,68 331,87 
EGR1 17,79 18,1 6,87 22,2 
FOS 4,57 5,73 5,67 10,58 
NR4A2 15,94 20,05 18,46 25,98 
RAET1L 4,97 4,8 5,76 1369,11 
TNF 195,68 276,67 133,49 168,26 
TNFRSF9 37,85 52,58 45,92 56,53 
TNFSF9 7,41 10,96 1,58 5,25 
ULBP2 11,9 14,25 11,62 604,46 
 
Table S5: Log fold change of mULBP2 target genes. 
 Sp1 20.02.19 NKs Sp1 07.06.19 NKs Sp1 24.06.19 NKs 
genes sULBP2 S2 ULBP2 
cells 
sULBP2 S2 ULBP2 
cells 
sULBP2 S2 ULBP2 
cells 
CCR6 -0,11 -1,89 -0,16 -1,04 0,03 -0,85 
CD69 -0,11 1,39 0,43 0,32 0,06 1,75 
EGR1 0,23 2,05 0,02 1,69 -0,06 2,47 
FOS 0,02 1,36 0,33 0,90 0,18 1,90 
NR4A2 -0,46 1,77 0,33 0,49 -0,11 2,25 
RAET1L 0,07 7,98 -0,05 7,89 -0,49 5,85 
TNF 0,01 1,90 0,50 0,33 -0,38 1,37 
TNFRSF9 -0,42 1,09 0,47 0,30 -0,62 1,63 
TNFSF9 0,20 2,61 0,56 1,73 0,24 3,39 
ULBP2 -0,10 5,08 0,26 5,70 -0,34 3,80 
 
Table S6: TPM values of sULBP2 target genes. 
 Sp1 20.02.19 NKs 
genes IL-2 + IL-15 sULBP2 S2 WT cells S2 ULBP2 cells 
ACOD1 0,00 0,09 0,00 0,00 
AQP9 0,00 0,13 0,00 0,00 
CEMIP 0,02 0,05 0,00 0,00 
CLEC4E 0,00 0,09 0,00 0,00 
CXCL8 0,00 0,40 0,00 1,25 
DSC1 0,03 0,32 0,15 0,00 
FRMD4A 0,00 0,07 0,00 0,00 
HHIPL1 0,00 0,07 0,00 0,10 
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IL1B 0,00 0,38 0,00 0,40 
INHBA 0,00 0,03 0,00 0,12 
NXPH4 0,22 0,54 1,05 0,45 
PLA2G7 0,00 0,19 0,00 0,00 
 
 Sp1 07.06.19 NKs 
genes IL-2 + IL-15 sULBP2 S2 WT cells S2 ULBP2 cells 
ACOD1 0,06 0,71 0,26 0,34 
AQP9 0,08 0,19 0,18 0,00 
CEMIP 0,02 0,06 0,15 0,00 
CLEC4E 0,00 0,11 0,00 0,00 
CXCL8 0,25 0,72 1,43 1,14 
DSC1 0,00 0,25 0,00 0,00 
FRMD4A 0,01 0,09 0,05 0,07 
HHIPL1 0,02 0,11 0,00 0,10 
IL1B 0,00 1,03 0,00 0,73 
INHBA 0,00 0,11 0,09 0,23 
NXPH4 2,75 28,26 3,13 3,73 
PLA2G7 0,12 0,52 0,28 0,00 
 
 Sp1 24.06.19 NKs 
genes IL-2 + IL-15 sULBP2 S2 WT cells S2 ULBP2 cells 
ACOD1 1,56 11,11 1,19 0,44 
AQP9 0,82 2,96 0,84 1,56 
CEMIP 0,36 1,32 0,68 0,50 
CLEC4E 0,13 2,02 0,77 0,43 
CXCL8 3,54 16,79 5,25 6,30 
DSC1 0,00 0,02 0,00 0,00 
FRMD4A 0,01 0,06 0,08 0,00 
HHIPL1 0,01 0,12 0,00 0,00 
IL1B 2,07 24,81 7,12 1,85 
INHBA 4,32 12,06 11,01 11,03 
NXPH4 0,97 2,20 28,16 24,84 
PLA2G7 2,10 5,88 2,98 1,41 
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Table S7: Log fold change of sULBP2 target genes. 
 Sp1 20.02.19 NKs Sp1 07.06.19 NKs Sp1 24.06.19 NKs 
Genes sULBP2 S2 ULBP2 
cells 
sULBP2 S2 ULBP2 
cells 
sULBP2 S2 ULBP2 
cells 
ACOD1 3,32 0,00 2,83 -1,42 3,45 0,39 
AQP9 3,78 0,00 1,83 0,88 1,19 -4,28 
CEMIP 1,18 0,00 1,86 -0,43 1,48 -3,99 
CLEC4E 3,28 0,00 3,86 -0,84 3,53 0,00 
CXCL8 5,35 6,98 2,24 0,26 1,51 -0,33 
DSC1 3,03 -3,98 1,66 0,00 4,69 0,00 
FRMD4A 2,97 0,00 2,01 -3,09 2,32 0,34 
HHIPL1 3,08 3,52 2,51 0,00 2,18 3,40 
IL1B 5,28 5,35 3,58 -1,93 6,70 6,20 
INHBA 1,99 3,75 1,48 0,00 3,56 1,31 
NXPH4 1,29 -1,19 1,18 -0,18 3,36 0,25 
PLA2G7 4,34 0,00 1,48 -1,07 2,04 -4,85 
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